Abstract
Exploiting the unique specificity of monoclonal antibodies has revolutionized the treatment and diagnosis of haematological and solid organ malignancies; bringing benefit to millions of patients over the past decades. Recent achievements include conjugating antibodies with toxic payloads resulting in superior efficacy and/or reduced toxicity, development of molecular imaging techniques targeting specific antigens for use as predictive and prognostic biomarkers, the development of novel bi- and tri-specific antibodies to enhance therapeutic benefit and abrogate resistance and the success of immunotherapy agents. In this chapter, we review an overview of antibody structure and function relevant to cancer therapy and provide an overview of pivotal clinical trials which have led to regulatory approval of monoclonal antibodies in cancer treatment. We further discuss resistance mechanisms and the unique side effects of each class of antibody and provide an overview of emerging therapeutic agents.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Adams CW, Allison DE, Flagella K, Presta L, Clarke J, Dybdal N et al (2006) Humanization of a recombinant monoclonal antibody to produce a therapeutic HER dimerization inhibitor, pertuzumab. Cancer Immunol Immunother 55(6):717–727
Aghajanian C, Blank SV, Goff BA, Judson PL, Teneriello MG, Husain A et al (2012) OCEANS: a randomized, double-blind, placebo-controlled phase III trial of chemotherapy with or without bevacizumab in patients with platinum-sensitive recurrent epithelial ovarian, primary peritoneal, or fallopian tube cancer. J Clin Oncol 30(17):2039–2045
Aghajanian C, Goff B, Nycum LR, Wang YV, Husain A, Blank SV (2015) Final overall survival and safety analysis of OCEANS, a phase 3 trial of chemotherapy with or without bevacizumab in patients with platinum-sensitive recurrent ovarian cancer. Gynecol Oncol 139(1):10–16
Amado RG, Wolf M, Peeters M, Van Cutsem E, Siena S, Freeman DJ et al (2008) Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer. J Clin Oncol 26(10):1626–1634
Andrulis IL, Bull SB, Blackstein ME, Sutherland D, Mak C, Sidlofsky S et al (1998) neu/erbB-2 amplification identifies a poor-prognosis group of women with node-negative breast cancer. Toronto Breast Cancer Study Group. J Clin Oncol 16(4):1340–1349
Ansell S, Armand P, Timmerman JM, Shipp MA, Garelik MBB, Zhu L et al (2015) Nivolumab in patients (pts) with relapsed or refractory classical Hodgkin lymphoma (R/R cHL): clinical outcomes from extended follow-up of a phase 1 study (CA209-039). Blood 126(23):583
Antonia SJ, López-Martin JA, Bendell J, Ott PA, Taylor M, Eder JP et al (2016) Nivolumab alone and nivolumab plus ipilimumab in recurrent small-cell lung cancer (CheckMate 032): a multicentre, open-label, phase 1/2 trial. Lancet Oncol 17(7):883–895
Arena S, Bellosillo B, Siravegna G, Martínez A, Cañadas I, Lazzari L et al (2015) Emergence of multiple EGFR extracellular mutations during cetuximab treatment in colorectal cancer. Clin Cancer Res 21(9):2157–2166
Armand P, Shipp MA, Ribrag V, Michot J-M, Zinzani PL, Kuruvilla J et al (2016) Programmed death-1 blockade with pembrolizumab in patients with classical Hodgkin lymphoma after brentuximab vedotin failure. J Clin Oncol 34(31):3733–3739
Avilés A, Nambo MJ, Neri N, Cleto S, Castañeda C, Huerta-Guzmàn J et al (2007) Dose dense (CEOP-14) vs dose dense and rituximab (CEOP-14+R) in high-risk diffuse large cell lymphoma. Med Oncol 24(1):85–89
Baig NA, Church AK, Nowakowski GS, Taylor RP, Lindorfer MA, Zent CS (2010) Complement activation and cytotoxicity in CLL cells treated with alemtuzumab and ofatumumab: evidence for multiple mechanisms of resistance to complement dependent cytotoxicity. Blood 116(21):3575
Baig NA, Taylor RP, Lindorfer MA, Church AK, Laplant BR, Pavey ES et al (2012) Complement dependent cytotoxicity in chronic lymphocytic leukemia: ofatumumab enhances alemtuzumab complement dependent cytotoxicity and reveals cells resistant to activated complement. Leuk Lymphoma 53(11):2218–2227
Bander NH (2013) Antibody–drug conjugate target selection: critical factors. Antibody-drug conjugates. Springer, Berlin, pp 29–40
Bang Y-J, Van Cutsem E, Feyereislova A, Chung HC, Shen L, Sawaki A et al (2010) Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet 376(9742):687–697
Bardelli A, Corso S, Bertotti A, Hobor S, Valtorta E, Siravegna G et al (2013) Amplification of the MET receptor drives resistance to anti-EGFR therapies in colorectal cancer. Cancer Discov 3(6):658–673
Bardia A, Vahdat LT, Diamond JR, Starodub A, Moroose RL, Isakoff SJ et al (2015) Therapy of refractory/relapsed metastatic triple-negative breast cancer (TNBC) with an anti-Trop-2-SN-38 antibody-drug conjugate (ADC), sacituzumab govitecan (IMMU-132): phase I/II clinical experience. Am Soc Clin Oncol
Bardia A, Mayer IA, Diamond JR, Moroose RL, Isakoff SJ, Starodub AN et al (2017) Efficacy and safety of anti-trop-2 antibody drug conjugate sacituzumab govitecan (IMMU-132) in heavily pretreated patients with metastatic triple-negative breast cancer. J Clin Oncol JCO. 2016.70. 8297
Barlesi F, Park K, Ciardiello F, von Pawel J, Gadgeel S, Hida T et al (2016) Primary analysis from OAK, a randomized phase III study comparing atezolizumab with docetaxel in 2L/3L NSCLC. Ann Oncol 27(Suppl 6):LBA44_PR
Barnett B, Ruter J, Brumlik M, Kryczek I, Cheng P, Zou W et al (eds) (2006) A phase II trial of denileukin diftitox to treat refractory advanced-stage ovarian cancer. In: ASCO Annual meeting proceedings
Barok M, Tanner M, Köninki K, Isola J (2011a) Trastuzumab-DM1 causes tumour growth inhibition by mitotic catastrophe in trastuzumab-resistant breast cancer cells in vivo. Breast Cancer Res 13(2):R46
Barok M, Tanner M, Köninki K, Isola J (2011b) Trastuzumab-DM1 is highly effective in preclinical models of HER2-positive gastric cancer. Cancer Lett 306(2):171–179
Barok M, Joensuu H, Isola J (2014) Trastuzumab emtansine: mechanisms of action and drug resistance. Breast Cancer Res BCR 16(2):209
Bazan J, Całkosiński I, Gamian A (2012) Phage display—a powerful technique for immunotherapy: 1. Introduction and potential of therapeutic applications. Human Vaccines Immunother 8(12):1817–1828
Behr T, Becker W, Hannappel E, Goldenberg DM, Wolf F (1995) Targeting of liver metastases of colorectal cancer with IgG, F(ab′)2, and Fab′ anti-carcinoembryonic antigen antibodies labeled with 99mTc: the role of metabolism and kinetics. Can Res 55(23 Suppl):5777s–5785s
Berchuck A, Kamel A, Whitaker R, Kerns B, Olt G, Kinney R et al (1990) Overexpression of HER-2/neu is associated with poor survival in advanced epithelial ovarian cancer. Can Res 50(13):4087–4091
Bergers G, Hanahan D (2008) Modes of resistance to anti-angiogenic therapy. Nat Rev Cancer 8(8):592–603
Bernardo SG, Moskalenko M, Pan M, Shah S, Sidhu HK, Sicular S et al (2013) Elevated rates of transaminitis during ipilimumab therapy for metastatic melanoma. Melanoma Res 23(1):47–54
Berns K, Horlings HM, Hennessy BT, Madiredjo M, Hijmans EM, Beelen K et al (2007) A functional genetic approach identifies the PI3K pathway as a major determinant of trastuzumab resistance in breast cancer. Cancer Cell 12(4):395–402
Bertotti A, Migliardi G, Galimi F, Sassi F, Torti D, Isella C et al (2011) A molecularly annotated platform of patient-derived xenografts (“xenopatients”) identifies HER2 as an effective therapeutic target in cetuximab-resistant colorectal cancer. Cancer Discov 1(6):508–523
Biehn SE, Kirk D, Rivera MP, Martinez AE, Khandani AH, Orlowski RZ (2006) Bronchiolitis obliterans with organizing pneumonia after rituximab therapy for non-Hodgkin’s lymphoma. Hematol Oncol 24(4):234–237
Bokemeyer C, Van Cutsem E, Rougier P, Ciardiello F, Heeger S, Schlichting M et al (2012) Addition of cetuximab to chemotherapy as first-line treatment for KRAS wild-type metastatic colorectal cancer: pooled analysis of the CRYSTAL and OPUS randomised clinical trials. Eur J Cancer 48(10):1466–1475
Bonner JA, Harari PM, Giralt J, Azarnia N, Shin DM, Cohen RB et al (2006) Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. N Engl J Med 354(6):567–578
Bonner JA, Harari PM, Giralt J, Cohen RB, Jones CU, Sur RK et al (2010) Radiotherapy plus cetuximab for locoregionally advanced head and neck cancer: 5-year survival data from a phase 3 randomised trial, and relation between cetuximab-induced rash and survival. Lancet Oncol 11(1):21–28
Bonomi P, Peterson P, Socinski M, Reck M, Paz-Ares L, Melosky B et al (2015) Rash as a marker for the efficacy of necitumumab in the SQUIRE Study. J Thorac Oncol
Boone SL, Rademaker A, Liu D, Pfeiffer C, Mauro DJ, Lacouture ME (2007) Impact and management of skin toxicity associated with anti-epidermal growth factor receptor therapy: survey results. Oncology 72(3–4):152–159
Borghaei H, Paz-Ares L, Horn L, Spigel DR, Steins M, Ready NE et al (2015) Nivolumab versus docetaxel in advanced nonsquamous non–small-cell lung cancer. N Engl J Med 373(17):1627–1639
Braghiroli MI, Sabbaga J, Hoff PM (2012) Bevacizumab: overview of the literature. Expert Rev Anticancer Ther 12(5):567–580
Brahmer J, Reckamp KL, Baas P, Crinò L, Eberhardt WE, Poddubskaya E et al (2015) Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer. N Engl J Med 373(2):123–135
Brandes AA, Bartolotti M, Tosoni A, Poggi R, Franceschi E (2015) Practical management of bevacizumab-related toxicities in glioblastoma. Oncologist 20(2):166–175
Bubien JK, Zhou L-J, Bell PD, Frizzell RA, Tedder TF (1993) Transfection of the CD20 cell surface molecule into ectopic cell types generates a Ca2+ conductance found constitutively in B lymphocytes. J Cell Biol 121(5):1121–1132
Burris HA, Rugo HS, Vukelja SJ, Vogel CL, Borson RA, Limentani S et al (2011) Phase II study of the antibody drug conjugate trastuzumab-DM1 for the treatment of human epidermal growth factor receptor 2 (HER2)–positive breast cancer after prior HER2-directed therapy. J Clin Oncol 29(4):398–405
Burstein HJ (2005) The distinctive nature of HER2-positive breast cancers. N Engl J Med 353(16):1652–1654
Buske C, Hoster E, Dreyling M, Eimermacher H, Wandt H, Metzner B et al (2009) The addition of rituximab to front-line therapy with CHOP (R-CHOP) results in a higher response rate and longer time to treatment failure in patients with lymphoplasmacytic lymphoma: results of a randomized trial of the German Low-Grade Lymphoma Study Group (GLSG). Leukemia 23(1):153–161
Camidge D, Heist R, Masters G, Scheff R, Starodub A, Messersmith W et al (eds) (2016) Therapy of metastatic, non-small cell lung cancer (mNSCLC) with the anti-Trop-2-SN-38 antibody-drug conjugate (ADC), sacituzumab govitecan (IMMU-132). In: ASCO meeting abstracts
Cardillo TM, Govindan SV, Sharkey RM, Trisal P, Goldenberg DM (2011) Humanized anti-Trop-2 IgG-SN-38 conjugate for effective treatment of diverse epithelial cancers: preclinical studies in human cancer xenograft models and monkeys. Clin Cancer Res 17(10):3157–3169
Cardillo TM, Govindan SV, Sharkey RM, Trisal P, Arrojo R, Liu D et al (2015) Sacituzumab govitecan (Immu-132), an anti-Trop-2/Sn-38 antibody–drug conjugate: characterization and efficacy in pancreatic, gastric, and other cancers. Bioconjug Chem 26(5):919–931
Cardillo TM, Sharkey RM, Rossi DL, Arrojo R, Mostafa A, Goldenberg DM (2017) Synthetic lethality exploitation by an anti-Trop-2-SN-38 antibody-drug conjugate, IMMU-132, plus PARP-inhibitors in BRCA1/2-wild-type triple-negative breast cancer. Clin Cancer Res. clincanres. 2401.016
Carlino MS, Atkinson V, Cebon JS, Jameson MB, Fitzharris BM, McNeil CM et al (2017) KEYNOTE-029: efficacy and safety of pembrolizumab (pembro) plus ipilimumab (ipi) for advanced melanoma. Am Soc Clin Oncol
Carmeliet P (2005) VEGF as a key mediator of angiogenesis in cancer. Oncology 69(Suppl 3):4–10
Carson KR, Evens AM, Richey EA, Habermann TM, Focosi D, Seymour JF et al (2009) Progressive multifocal leukoencephalopathy after rituximab therapy in HIV-negative patients: a report of 57 cases from the Research on Adverse Drug Events and Reports project. Blood 113(20):4834–4840
Cella D, Grünwald V, Nathan P, Doan J, Dastani H, Taylor F et al (2016) Quality of life in patients with advanced renal cell carcinoma given nivolumab versus everolimus in CheckMate 025: a randomised, open-label, phase 3 trial. Lancet Oncol 17(7):994–1003
Chames P, Van Regenmortel M, Weiss E, Baty D (2009) Therapeutic antibodies: successes, limitations and hopes for the future. Br J Pharmacol 157(2):220–233
Chen R, Hou J, Newman E, Kim Y, Donohue C, Liu X et al (2015) CD30 downregulation, MMAE resistance, and MDR1 upregulation are all associated with resistance to brentuximab vedotin. Mol Cancer Ther 14(6):1376–1384
Chen R, Gopal AK, Smith SE, Ansell SM, Rosenblatt JD, Savage KJ et al (2016a) Five-year survival and durability results of brentuximab vedotin in patients with relapsed or refractory Hodgkin lymphoma. Blood. blood-2016-02-699850
Chen R, Zinzani P, Fanale M, Armand P, Johnson N, Ribrag V et al (2016b) Pembrolizumab for relapsed/refractory classical Hodgkin lymphoma (R/R cHL): phase 2 KEYNOTE-087 study. J Clin Oncol 34
Chinot OL, Wick W, Mason W, Henriksson R, Saran F, Nishikawa R et al (2014) Bevacizumab plus radiotherapy–temozolomide for newly diagnosed glioblastoma. N Engl J Med 370(8):709–722
Choueiri TK, Hodi FS, Thompson JA, McDermott DF, Hwu W-J, Lawrence DP et al (2017) Pembrolizumab (pembro) plus low-dose ipilimumab (ipi) for patients (pts) with advanced renal cell carcinoma (RCC): phase 1 KEYNOTE-029 study. Am Soc Clin Oncol
Chow LQ, Haddad R, Gupta S, Mahipal A, Mehra R, Tahara M et al (2016) Antitumor activity of pembrolizumab in biomarker-unselected patients with recurrent and/or metastatic head and neck squamous cell carcinoma: results from the phase Ib KEYNOTE-012 expansion cohort. J Clin Oncol 34(32):3838–3845
Chowdhury S, McDermott DF, Voss MH, Hawkins RE, Aimone P, Voi M et al (2017) A phase I/II study to assess the safety and efficacy of pazopanib (PAZ) and pembrolizumab (PEM) in patients (pts) with advanced renal cell carcinoma (aRCC). Am Soc Clin Oncol
Chung CH, Mirakhur B, Chan E, Le Q-T, Berlin J, Morse M et al (2008) Cetuximab-induced anaphylaxis and IgE specific for galactose-α-1, 3-galactose. N Engl J Med 358(11):1109–1117
Cloughesy T, Vredenburgh J, Day B, Das A, Friedman H (2010) Updated safety and survival of patients with relapsed glioblastoma treated with bevacizumab in the BRAIN study. J Clin Oncol 28(15 Suppl):2008
Cobleigh MA, Vogel CL, Tripathy D, Robert NJ, Scholl S, Fehrenbacher L et al (1999) Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease. J Clin Oncol 17(9):2639
Cohen SB, Emery P, Greenwald MW, Dougados M, Furie RA, Genovese MC et al (2006) Rituximab for rheumatoid arthritis refractory to anti–tumor necrosis factor therapy: results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeks. Arthritis Rheum 54(9):2793–2806
Coiffier B, Haioun C, Ketterer N, Engert A, Tilly H, Ma D et al (1998) Rituximab (anti-CD20 monoclonal antibody) for the treatment of patients with relapsing or refractory aggressive lymphoma: a multicenter phase II study. Blood 92(6):1927–1932
Coiffier B, Lepretre S, Pedersen LM, Gadeberg O, Fredriksen H, van Oers MH et al (2008) Safety and efficacy of ofatumumab, a fully human monoclonal anti-CD20 antibody, in patients with relapsed or refractory B-cell chronic lymphocytic leukemia: a phase 1-2 study. Blood 111(3):1094–1100
Coiffier B, Thieblemont C, Van Den Neste E, Lepeu G, Plantier I, Castaigne S et al (2010) Long-term outcome of patients in the LNH-98.5 trial, the first randomized study comparing rituximab-CHOP to standard CHOP chemotherapy in DLBCL patients: a study by the Groupe d’Etudes des Lymphomes de l’Adulte. Blood 116(12):2040–2045
Corsello SM, Barnabei A, Marchetti P, De Vecchis L, Salvatori R, Torino F (2013) Endocrine side effects induced by immune checkpoint inhibitors. J Clin Endocrinol Metab 98(4):1361–1375
Damle RN, Wasil T, Fais F, Ghiotto F, Valetto A, Allen SL et al (1999) Ig V gene mutation status and CD38 expression as novel prognostic indicators in chronic lymphocytic leukemia. Blood 94(6):1840–1847
de Claro RA, McGinn K, Kwitkowski V, Bullock J, Khandelwal A, Habtemariam B et al (2012) US Food and Drug Administration approval summary: brentuximab vedotin for the treatment of relapsed Hodgkin lymphoma or relapsed systemic anaplastic large-cell lymphoma. Clin Cancer Res 18(21):5845–5849
Deaglio S, Mehta K, Malavasi F (2001) Human CD38: a (r) evolutionary story of enzymes and receptors. Leuk Res 25(1):1–12
Desjarlais JR, Lazar GA (2011) Modulation of antibody effector function. Exp Cell Res 317(9):1278–1285
Desjarlais JR, Lazar GA, Zhukovsky EA, Chu SY (2007) Optimizing engagement of the immune system by anti-tumor antibodies: an engineer’s perspective. Drug Discov Today 12(21–22):898–910
Dhomen NS, Mariadason J, Tebbutt N, Scott AM (2012) Therapeutic targeting of the epidermal growth factor receptor in human cancer. Crit Rev Oncog 17(1)
Dieras V, Harbeck N, Albain K, Burris H, Awada A, Crivellari D et al (2010) Abstract P3-14-01: a phase Ib/II trial of trastuzumab-DM1 with pertuzumab for patients with HER2-positive, locally advanced or metastatic breast cancer: interim efficacy and safety results. Cancer Res 70(24 Suppl):P3-14-01-P3-14-01
DiLillo DJ, Ravetch JV (2015) Differential Fc-receptor engagement drives an anti-tumor vaccinal effect. Cell 161(5):1035–1045
Dimopoulos MA, Oriol A, Nahi H, San-Miguel J, Bahlis NJ, Usmani SZ et al (2016) Daratumumab, lenalidomide, and dexamethasone for multiple myeloma. N Engl J Med 375(14):1319–1331
DiPippo VA, Olson WC, Nguyen HM, Brown LG, Vessella RL, Corey E (2015) Efficacy studies of an antibody-drug conjugate PSMA-ADC in patient-derived prostate cancer xenografts. Prostate 75(3):303–313
Dotan E, Cohen SJ, Starodub AN, Lieu CH, Messersmith WA, Guarino MJ et al (eds) (2016) Labetuzumab govitecan (IMMU-130), an anti-CEACAM5/SN-38 antibody-drug conjugate, is active in patients (pts) with heavily pretreated metastatic colorectal cancer (mCRC): phase II results. Cancer Res (Amer Assoc Cancer Research 615 Chestnut St, 17th Floor, Philadelphia, PA 19106-4404 USA)
Douillard J-Y, Siena S, Cassidy J, Tabernero J, Burkes R, Barugel M et al (2010) Randomized, phase III trial of panitumumab with infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX4) versus FOLFOX4 alone as first-line treatment in patients with previously untreated metastatic colorectal cancer: the PRIME study. J Clin Oncol 28(31):4697–4705
Douillard J-Y, Oliner KS, Siena S, Tabernero J, Burkes R, Barugel M et al (2013) Panitumumab–FOLFOX4 treatment and RAS mutations in colorectal cancer. N Engl J Med 369(11):1023–1034
Duncan AR, Winter G (1988) The binding site for C1q on IgG. Nature 332(6166):738–740
Dürkop H, Foss HD, Eitelbach F, Anagnostopoulos I, Latza U, Pileri S et al (2000) Expression of the CD30 antigen in non-lymphoid tissues and cells. J Pathol 190(5):613–618
Eggermont AM, Chiarion-Sileni V, Grob J-J, Dummer R, Wolchok JD, Schmidt H et al (2015) Adjuvant ipilimumab versus placebo after complete resection of high-risk stage III melanoma (EORTC 18071): a randomised, double-blind, phase 3 trial. Lancet Oncol 16(5):522–530
Eggermont AM, Chiarion-Sileni V, Grob J-J, Dummer R, Wolchok JD, Schmidt H et al (2016) Prolonged survival in stage III melanoma with ipilimumab adjuvant therapy. N Engl J Med 375(19):1845–1855
Elinzano H, Hebda N, Luppe D (2016) PSMA ADC for progressive glioblastoma: phase II Brown University Oncology Research Group Study. J Clin Oncol 34
Ensslin CJ, Rosen AC, Wu S, Lacouture ME (2013) Pruritus in patients treated with targeted cancer therapies: systematic review and meta-analysis. J Am Acad Dermatol 69(5):708–720
Eremina V, Sood M, Haigh J, Nagy A, Lajoie G, Ferrara N et al (2003) Glomerular-specific alterations of VEGF-A expression lead to distinct congenital and acquired renal diseases. J Clin Investig 111(5):707–716
Escudier B, Bellmunt J, Négrier S, Bajetta E, Melichar B, Bracarda S et al (2010) Phase III trial of bevacizumab plus interferon alfa-2a in patients with metastatic renal cell carcinoma (AVOREN): final analysis of overall survival. J Clin Oncol 28(13):2144–2150
Estenfelder S, Tausch E, Robrecht S, Bahlo J, Goede V, Ritgen M et al (2016) Gene mutations and treatment outcome in the context of chlorambucil (Clb) without or with the addition of rituximab (R) or obinutuzumab (GA-101, G)-results of an extensive analysis of the phase III study CLL11 of the German CLL study group. Am Soc Hematol
Eve HE, Linch D, Qian W, Ross M, Seymour JF, Smith P et al (2009) Toxicity of fludarabine and cyclophosphamide with or without rituximab as initial therapy for patients with previously untreated mantle cell lymphoma: results of a randomised phase II study. Leuk Lymphoma 50(2):211–215
Fakih M, Vincent M (2010) Adverse events associated with anti-EGFR therapies for the treatment of metastatic colorectal cancer. Curr Oncol 17(S1)
Fanning LJ, Connor AM, Wu GE (1996) Development of the immunoglobulin repertoire. Clin Immunol Immunopathol 79(1):1–14
Fehrenbacher L, Spira A, Ballinger M, Kowanetz M, Vansteenkiste J, Mazieres J et al (2016) Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial. Lancet 387(10030):1837–1846
Ferrajoli A, O’Brien SM, Cortes JE, Giles FJ, Thomas DA, Faderl S et al (2003) Phase II study of alemtuzumab in chronic lymphoproliferative disorders. Cancer 98(4):773–778
Ferrara N (2010) Pathways mediating VEGF-independent tumor angiogenesis. Cytokine Growth Factor Rev 21(1):21–26
Ferrara N, Hillan KJ, Gerber H-P, Novotny W (2004) Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer. Nat Rev Drug Discov 3(5):391–400
Ferris RL, Jaffee EM, Ferrone S (2010) Tumor antigen-targeted, monoclonal antibody-based immunotherapy: clinical response, cellular immunity, and immunoescape. J Clin Oncol 28(28):4390–4399
Ferris RL, Blumenschein G Jr, Fayette J, Guigay J, Colevas AD, Licitra L et al (2016) Nivolumab for recurrent squamous-cell carcinoma of the head and neck. N Engl J Med 2016(375):1856–1867
Feugier P, Van Hoof A, Sebban C, Solal-Celigny P, Bouabdallah R, Ferme C et al (2005) Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma: a study by the Groupe d’Etude des Lymphomes de l’Adulte. J Clin Oncol 23(18):4117–4126
Fischer K, Bahlo J, Fink A-M, Busch R, Böttcher S, Mayer J et al (2012) Extended follow up of the CLL8 protocol, a randomized phase-III trial of the German CLL Study Group (GCLLSG) comparing fludarabine and cyclophosphamide (FC) to FC plus rituximab (FCR) for previously untreated patients with chronic lymphocytic leukemia (CLL): results on survival, progression-free survival, delayed neutropenias and secondary malignancies confirm superiority of the FCR regimen. Am Soc Hematol
Flanagan RJ, Jones AL (2004) Fab antibody fragments: some applications in clinical toxicology. Drug Saf 27(14):1115–1133
Flavell DJ, Noss A, Pulford KA, Ling N, Flavell SU (1997) Systemic therapy with 3BIT, a triple combination cocktail of anti-CD19,-CD22, and-CD38-saporin immunotoxins, is curative of human B-cell lymphoma in severe combined immunodeficient mice. Can Res 57(21):4824–4829
Francisco JA, Cerveny CG, Meyer DL, Mixan BJ, Klussman K, Chace DF et al (2003) cAC10-vcMMAE, an anti-CD30–monomethyl auristatin E conjugate with potent and selective antitumor activity. Blood 102(4):1458–1465
Fraser G, Smith C, Imrie K, Meyer R (2007) Care HDSGoCCOsPiE-B. Alemtuzumab in chronic lymphocytic leukemia. Curr Oncol 14(3):96 (Toronto)
Frattini M, Saletti P, Romagnani E, Martin V, Molinari F, Ghisletta M et al (2007) PTEN loss of expression predicts cetuximab efficacy in metastatic colorectal cancer patients. Br J Cancer 97(8):1139–1145
Freudenberg JA, Wang Q, Katsumata M, Drebin J, Nagatomo I, Greene MI (2009) The role of HER2 in early breast cancer metastasis and the origins of resistance to HER2-targeted therapies. Exp Mol Pathol 87(1):1–11
Friedman HS, Prados MD, Wen PY, Mikkelsen T, Schiff D, Abrey LE et al (2009) Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma. J Clin Oncol 27(28):4733–4740
Fuchs CS, Tomasek J, Yong CJ, Dumitru F, Passalacqua R, Goswami C et al (2014) Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (REGARD): an international, randomised, multicentre, placebo-controlled, phase 3 trial. Lancet 383(9911):31–39
Gan HK, Burgess AW, Clayton AH, Scott AM (2012) Targeting of a conformationally exposed, tumor-specific epitope of EGFR as a strategy for cancer therapy. Can Res 72(12):2924–2930
Garnock-Jones KP (2013) Brentuximab vedotin: a review of its use in patients with Hodgkin lymphoma and systemic anaplastic large cell lymphoma following previous treatment failure. Drugs 73(4):371–381
Garon EB, Ciuleanu T-E, Arrieta O, Prabhash K, Syrigos KN, Goksel T et al (2014) Ramucirumab plus docetaxel versus placebo plus docetaxel for second-line treatment of stage IV non-small-cell lung cancer after disease progression on platinum-based therapy (REVEL): a multicentre, double-blind, randomised phase 3 trial. Lancet 384(9944):665–673
Garon EB, Rizvi NA, Hui R, Leighl N, Balmanoukian AS, Eder JP et al (2015) Pembrolizumab for the treatment of non-small-cell lung cancer. N Engl J Med 372(21):2018–2028
Garrett JT, Arteaga CL (2011) Resistance to HER2-directed antibodies and tyrosine kinase inhibitors: mechanisms and clinical implications. Cancer Biol Ther 11(9):793–800
Garrett TP, McKern NM, Lou M, Elleman TC, Adams TE, Lovrecz GO et al (2002) Crystal structure of a truncated epidermal growth factor receptor extracellular domain bound to transforming growth factor α. Cell 110(6):763–773
Gerena-Lewis M, Crawford J, Bonomi P, Maddox AM, Hainsworth J, McCune DE et al (2009) A phase II trial of Denileukin Diftitox in patients with previously treated advanced non-small cell lung cancer. Am J Clin Oncol 32(3):269–273
Ghielmini M, Rufibach K, Salles G, Leoncini-Franscini L, Leger-Falandry C, Cogliatti S et al (2005) Single agent rituximab in patients with follicular or mantle cell lymphoma: clinical and biological factors that are predictive of response and event-free survival as well as the effect of rituximab on the immune system: a study of the Swiss Group for Clinical Cancer Research (SAKK). Ann Oncol 16(10):1675–1682
Gianni L, Pienkowski T, Im Y-H, Roman L, Tseng L-M, Liu M-C et al (2012) Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial. Lancet Oncol 13(1):25–32
Giantonio BJ, Catalano PJ, Meropol NJ, O’Dwyer PJ, Mitchell EP, Alberts SR et al (2007) Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: results from the Eastern Cooperative Oncology Group Study E3200. J Clin Oncol 25(12):1539–1544
Ginaldi L, De Martinis M, Matutes E, Farahat N, Morilla R, Dyer MJ et al (1998) Levels of expression of CD52 in normal and leukemic B and T cells: correlation with in vivo therapeutic responses to Campath-1H. Leuk Res 22(2):185–191
Goede V, Fischer K, Busch R, Engelke A, Eichhorst B, Wendtner CM et al (2014) Obinutuzumab plus chlorambucil in patients with CLL and coexisting conditions. N Engl J Med 370(12):1101–1110
Goede V, Fischer K, Bosch F, Follows G, Frederiksen H, Cuneo A et al (2015) Updated survival analysis from the CLL11 study: obinutuzumab versus rituximab in chemoimmunotherapy-treated patients with chronic lymphocytic leukemia. Blood 126(23):1733
Goldenberg DM, Cardillo TM, Govindan SV, Rossi EA, Sharkey RM (2015) Trop-2 is a novel target for solid cancer therapy with sacituzumab govitecan (IMMU-132), an antibody-drug conjugate (ADC). Oncotarget 6(26):22496
Gopal AK, Press OW (1999) Clinical applications of anti-CD20 antibodies. J Lab Clin Med 134(5):445–450
Gopal AK, Chen R, Smith SE, Ansell SM, Rosenblatt JD, Savage KJ et al (2014) Durable remissions in a pivotal phase 2 study of brentuximab vedotin in relapsed or refractory Hodgkin lymphoma. Blood. blood-2014-08-595801
Gordon LI, Molina A, Witzig T, Emmanouilides C, Raubtischek A, Darif M et al (2004) Durable responses after ibritumomab tiuxetan radioimmunotherapy for CD20+ B-cell lymphoma: long-term follow-up of a phase 1/2 study. Blood 103(12):4429–4431
Govindan SV, Cardillo TM, Rossi EA, McBride WJ, Sharkey RM, Goldenberg DM (2015) IMMU-130, a unique antibody-drug conjugate (ADC) of SN-38 targeting CEACAM5 antigen: preclinical basis for clinical activity in metastatic colorectal cancer (mCRC). Am Soc Clin Oncol
Gowryshankar A, Nagaraja V, Eslick GD (2013) HER2 status in Barrett’s esophagus & esophageal cancer: a meta analysis. J Gastrointest Oncol 5(1):25–35
Grazette LP, Boecker W, Matsui T, Semigran M, Force TL, Hajjar RJ et al (2004) Inhibition of ErbB2 causes mitochondrial dysfunction in cardiomyocytes. J Am Coll Cardiol 44(11):2231–2238
Grushko T, Filiaci V, Mundt A, Ridderstråle K, Olopade O, Fleming G (2008) An exploratory analysis of HER-2 amplification and overexpression in advanced endometrial carcinoma: a Gynecologic Oncology Group study. Gynecol Oncol 108(1):3–9
Guidetti A, Carlo-Stella C, Ruella M, Miceli R, Devizzi L, Locatelli SL et al (2011) Myeloablative doses of yttrium-90-ibritumomab tiuxetan and the risk of secondary myelodysplasia/acute myelogenous leukemia. Cancer 117(22):5074–5084
Habermann TM, Weller EA, Morrison VA, Gascoyne RD, Cassileth PA, Cohn JB et al (2006) Rituximab-CHOP versus CHOP alone or with maintenance rituximab in older patients with diffuse large B-cell lymphoma. J Clin Oncol 24(19):3121–3127
Haense N, Atmaca A, Pauligk C, Steinmetz K, Marmé F, Haag G-M et al (2016) A phase I trial of the trifunctional anti Her2 × anti CD3 antibody ertumaxomab in patients with advanced solid tumors. BMC Cancer 16(1):420
Hagenbeek A, Bischof-Delaloye A, Radford JA, Rohatiner A, Salles G, Van Hoof A et al (2007) 90Y-Ibritumomab Tiuxetan (Zevalin®) consolidation of first remission in advanced stage follicular non-Hodgkin’s lymphoma: first results of the international randomized phase 3 first-line indolent trial (FIT) in 414 patients. Am Soc Hematol
Hainsworth JD, Spigel DR, Markus TM, Shipley D, Thompson D, Rotman R et al (2009) Rituximab plus short-duration chemotherapy followed by Yttrium-90 Ibritumomab tiuxetan as first-line treatment for patients with follicular non-Hodgkin lymphoma: a phase II trial of the Sarah Cannon Oncology Research Consortium. Clin Lymphoma Myeloma 9(3):223–228
Halim A, Bagley RG, Keler T (2016) Glycoprotein NMB (gpNMB) overexpression is prevalent in human cancers: pancreatic cancer, non-small cell lung cancer, head and neck cancer, and osteosarcoma. AACR
Hallek M, Fischer K, Fingerle-Rowson G, Fink A, Busch R, Mayer J et al (2010) Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial. Lancet 376(9747):1164–1174
Hamid O, Robert C, Daud A, Hodi FS, Hwu W-J, Kefford R et al (2013) Safety and tumor responses with lambrolizumab (anti–PD-1) in melanoma. N Engl J Med 369(2):134–144
Hamid O, Puzanov I, Dummer R, Schachter J, Daud A, Schadendorf D et al (2016) Final overall survival for KEYNOTE-002: pembrolizumab (pembro) versus investigator-choice chemotherapy (chemo) for ipilimumab (ipi)-refractory melanoma. Ann Oncol 27(suppl 6):1107O
Hammers H, Plimack E, Infante J, Ernstoff M, Rini B, Mcdermott D et al (2014) Phase I study of nivolumab in combination with ipilimumab (ipi) in metastatic renal cell carcinoma (mrcc). BJU Int 114:8
Hansen HJ, Jones AL, Sharkey RM, Grebenau R, Blazejewski N, Kunz A et al (1990) Preclinical evaluation of an “instant” 99mTc-labeling kit for antibody imaging. Can Res 50(3 Suppl):794s–798s
Hapani S, Chu D, Wu S (2009) Risk of gastrointestinal perforation in patients with cancer treated with bevacizumab: a meta-analysis. Lancet Oncol 10(6):559–568
Hapani S, Sher A, Chu D, Wu S (2010) Increased risk of serious hemorrhage with bevacizumab in cancer patients: a meta-analysis. Oncology 79(1–2):27–38
Heiss MM, Murawa P, Koralewski P, Kutarska E, Kolesnik OO, Ivanchenko VV et al (2010) The trifunctional antibody catumaxomab for the treatment of malignant ascites due to epithelial cancer: results of a prospective randomized phase II/III trial. Int J Cancer 127(9):2209–2221
Hellmann MD, Rizvi NA, Goldman JW, Gettinger SN, Borghaei H, Brahmer JR et al (2017) Nivolumab plus ipilimumab as first-line treatment for advanced non-small-cell lung cancer (CheckMate 012): results of an open-label, phase 1, multicohort study. Lancet Oncol 18(1):31–41
Herbst RS, Baas P, Kim D-W, Felip E, Pérez-Gracia JL, Han J-Y et al (2016) Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial. Lancet 387(10027):1540–1550
Heresi GA, Farver CF, Stoller JK (2008) Interstitial pneumonitis and alveolar hemorrhage complicating use of rituximab. Respiration 76(4):449–453
Herrera L, Farah R, Pellegrini V, Aquino D, Sandler E, Buchanan G et al (2000) Immunotoxins against CD19 and CD22 are effective in killing precursor-B acute lymphoblastic leukemia cells in vitro. Leukemia 14(5):853–858
Hillen F, Griffioen AW (2007) Tumour vascularization: sprouting angiogenesis and beyond. Cancer Metastasis Rev 26(3–4):489–502
Hillmen P, Skotnicki AB, Robak T, Jaksic B, Dmoszynska A, Wu J et al (2007) Alemtuzumab compared with chlorambucil as first-line therapy for chronic lymphocytic leukemia. J Clin Oncol 25(35):5616–5623
Hillmen P, Robak T, Janssens A, Babu KG, Kloczko J, Grosicki S et al (2015) Chlorambucil plus ofatumumab versus chlorambucil alone in previously untreated patients with chronic lymphocytic leukaemia (COMPLEMENT 1): a randomised, multicentre, open-label phase 3 trial. Lancet 385(9980):1873–1883
Hobor S, Van Emburgh BO, Crowley E, Misale S, Di Nicolantonio F, Bardelli A (2014) TGFα and amphiregulin paracrine network promotes resistance to EGFR blockade in colorectal cancer cells. Clin Cancer Res 20(24):6429–6438
Hodi FS, O’Day SJ, McDermott DF, Weber RW, Sosman JA, Haanen JB et al (2010a) Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 363(8):711–723
Hodi FS, O’day SJ, McDermott DF, Weber RW, Sosman JA, Haanen JB et al (2010b) Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 2010(363):711–723
Hodi FS, Chesney J, Pavlick AC, Robert C, Grossmann KF, McDermott DF et al (2016) Combined nivolumab and ipilimumab versus ipilimumab alone in patients with advanced melanoma: 2-year overall survival outcomes in a multicentre, randomised, controlled, phase 2 trial. Lancet Oncol 17(11):1558–1568
Hogarth PM, Pietersz GA (2012) Fc receptor-targeted therapies for the treatment of inflammation, cancer and beyond. Nat Rev Drug Discov 11(4):311–331
Holliger P, Hudson PJ (2005) Engineered antibody fragments and the rise of single domains. Nat Biotechnol 23(9):1126–1136
Holmes K, Roberts OL, Thomas AM, Cross MJ (2007) Vascular endothelial growth factor receptor-2: structure, function, intracellular signalling and therapeutic inhibition. Cell Signal 19(10):2003–2012
Holmgaard RB, Zamarin D, Munn DH, Wolchok JD, Allison JP (2013) Indoleamine 2, 3-dioxygenase is a critical resistance mechanism in antitumor T cell immunotherapy targeting CTLA-4. J Exp Med jem. 20130066
Horn L, Brahmer J, Reck M, Borghaei H, Spigel D, Steins M et al (2015) 417OPhase 3, randomized trial (CheckMate 057) of nivolumab vs docetaxel in advanced non-squamous (non-SQ) non-small cell lung cancer (NSCLC): subgroup analyses and patient reported outcomes (PROs). Ann Oncol 26(suppl 9):ix125-ix
Horning SJ, Younes A, Jain V, Kroll S, Lucas J, Podoloff D et al (2005) Efficacy and safety of tositumomab and iodine-131 tositumomab (Bexxar) in B-cell lymphoma, progressive after rituximab. J Clin Oncol 23(4):712–719
Hsi ED, Steinle R, Balasa B, Szmania S, Draksharapu A, Shum BP et al (2008) CS1, a potential new therapeutic antibody target for the treatment of multiple myeloma. Clin Cancer Res 14(9):2775–2784
Hudis CA (2007) Trastuzumab—mechanism of action and use in clinical practice. N Engl J Med 357(1):39–51
Hugo W, Zaretsky JM, Sun L, Song C, Moreno BH, Hu-Lieskovan S et al (2016) Genomic and transcriptomic features of response to anti-PD-1 therapy in metastatic melanoma. Cell 165(1):35–44
Hurvitz SA, Dirix L, Kocsis J, Bianchi GV, Lu J, Vinholes J et al (2013) Phase II randomized study of trastuzumab emtansine versus trastuzumab plus docetaxel in patients with human epidermal growth factor receptor 2–positive metastatic breast cancer. J Clin Oncol JCO. 2012.44. 9694
Hurwitz H, Fehrenbacher L, Novotny W, Cartwright T, Hainsworth J, Heim W et al (2004) Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 350(23):2335–2342
Iida M, Brand TM, Starr MM, Li C, Huppert EJ, Luthar N et al (2013) Sym004, a novel EGFR antibody mixture, can overcome acquired resistance to cetuximab. Neoplasia 15(10):1196–1206
Jacobs SA, Swerdlow SH, Kant J, Foon KA, Jankowitz R, Land SR et al (2008) Phase II trial of short-course CHOP-R followed by 90Y-ibritumomab tiuxetan and extended rituximab in previously untreated follicular lymphoma. Clin Cancer Res 14(21):7088–7094
Jawa Z, Perez RM, Garlie L, Singh M, Qamar R, Khandheria BK et al (2016) Risk factors of trastuzumab-induced cardiotoxicity in breast cancer: a meta-analysis. Medicine 95(44):e5195
Johns TG, Stockert E, Ritter G, Jungbluth AA, Huang HJS, Cavenee WK et al (2002) Novel monoclonal antibody specific for the de2-7 epidermal growth factor receptor (EGFR) that also recognizes the EGFR expressed in cells containing amplification of the EGFR gene. Int J Cancer 98(3):398–408
Johnson DH, Fehrenbacher L, Novotny WF, Herbst RS, Nemunaitis JJ, Jablons DM et al (2004) Randomized phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small-cell lung cancer. J Clin Oncol 22(11):2184–2191
Jonker DJ, O’callaghan CJ, Karapetis CS, Zalcberg JR, Tu D, Au H-J et al (2007) Cetuximab for the treatment of colorectal cancer. N Engl J Med 357(20):2040–2048
Junttila TT, Li G, Parsons K, Phillips GL, Sliwkowski MX (2011) Trastuzumab-DM1 (T-DM1) retains all the mechanisms of action of trastuzumab and efficiently inhibits growth of lapatinib insensitive breast cancer. Breast Cancer Res Treat 128(2):347–356
Kang HJ, Park JS, Kim D-W, Lee J, Jeong YJ, Choi SM et al (2012) Adverse pulmonary reactions associated with the use of monoclonal antibodies in cancer patients. Respir Med 106(3):443–450
Karapetis CS, Khambata-Ford S, Jonker DJ, O’callaghan CJ, Tu D, Tebbutt NC et al (2008) K-ras mutations and benefit from cetuximab in advanced colorectal cancer. New Engl J Med 359(17):1757–1765
Kasi PM, Tawbi HA, Oddis CV, Kulkarni HS (2012) Clinical review: serious adverse events associated with the use of rituximab-a critical care perspective. Crit Care 16(4):231
Kataoka Y, Mukohara T, Shimada H, Saijo N, Hirai M, Minami H (2010) Association between gain-of-function mutations in PIK3CA and resistance to HER2-targeted agents in HER2-amplified breast cancer cell lines. Ann Oncol 21(2):255–262
Kaufman HL, Russell J, Hamid O, Bhatia S, Terheyden P, D’Angelo SP et al (2016) Avelumab in patients with chemotherapy-refractory metastatic Merkel cell carcinoma: a multicentre, single-group, open-label, phase 2 trial. Lancet Oncol 17(10):1374–1385
Kawashima O, Kamiyoshihara M, Sakata S, Endo K, Saito R, Morishita Y (2000) The clinicopathological significance of preoperative serum-soluble interleukin-2 receptor concentrations in operable non-small-cell lung cancer patients. Ann Surg Oncol 7(3):239–245
Keating MJ, Flinn I, Jain V, Binet J-L, Hillmen P, Byrd J et al (2002) Therapeutic role of alemtuzumab (Campath-1H) in patients who have failed fludarabine: results of a large international study. Blood 99(10):3554–3561
Kerbel RS (2008) Tumor angiogenesis. N Engl J Med 358(19):2039–2049
Kim KW, Ramaiya NH, Krajewski KM, Jagannathan JP, Tirumani SH, Srivastava A et al (2013) Ipilimumab associated hepatitis: imaging and clinicopathologic findings. Invest New Drugs 31(4):1071–1077
Klapper LN, Glathe S, Vaisman N, Hynes NE, Andrews GC, Sela M et al (1999) The ErbB-2/HER2 oncoprotein of human carcinomas may function solely as a shared coreceptor for multiple stroma-derived growth factors. Proc Natl Acad Sci 96(9):4995–5000
Klepfish A, Gilles L, Ioannis K, Eliezer R, Ami S (2009) Enhancing the action of rituximab in chronic lymphocytic leukemia by adding fresh frozen plasma. Ann N Y Acad Sci 1173(1):865–873
Klos KS, Zhou X, Lee S, Zhang L, Yang W, Nagata Y et al (2003) Combined trastuzumab and paclitaxel treatment better inhibits ErbB-2-mediated angiogenesis in breast carcinoma through a more effective inhibition of Akt than either treatment alone. Cancer 98(7):1377–1385
Knox SJ, Goris ML, Trisler K, Negrin R, Davis T, Liles T-M et al (1996) Yttrium-90-labeled anti-CD20 monoclonal antibody therapy of recurrent B-cell lymphoma. Clin Cancer Res 2(3):457–470
Kobayashi Y, Komatsu Y, Yuki S, Fukushima H, Sasaki T, Iwanaga I et al (2015) Randomized controlled trial on the skin toxicity of panitumumab in Japanese patients with metastatic colorectal cancer: HGCSG1001 study; J-STEPP. Future Oncol 11(4):617–627
Kohler G, Milstein C (1975) Continuous cultures of fused cells secreting antibody of predefined specificity. Nature 256(5517):495–497
Kosmas C, Stamatopoulos K, Stavroyianni N, Tsavaris N, Papadaki T (2002) Anti-CD20-based therapy of B cell lymphoma: state of the art. Leukemia 16(10):2004
Kreitman RJ (2009) Recombinant immunotoxins containing truncated bacterial toxins for the treatment of hematologic malignancies. BioDrugs 23(1):1–13
Kruser TJ, Wheeler DL (2010) Mechanisms of resistance to HER family targeting antibodies. Exp Cell Res 316(7):1083–1100
Kumaresan PR, Lai WC, Chuang SS, Bennett M, Mathew PA (2002) CS1, a novel member of the CD2 family, is homophilic and regulates NK cell function. Mol Immunol 39(1):1–8
Kuramochi Y, Guo X, Sawyer DB (2006) Neuregulin activates erbB2-dependent src/FAK signaling and cytoskeletal remodeling in isolated adult rat cardiac myocytes. J Mol Cell Cardiol 41(2):228–235
Lacouture ME, Mitchell EP, Piperdi B, Pillai MV, Shearer H, Iannotti N et al (2010) Skin toxicity evaluation protocol with panitumumab (STEPP), a phase II, open-label, randomized trial evaluating the impact of a pre-Emptive Skin treatment regimen on skin toxicities and quality of life in patients with metastatic colorectal cancer. J Clin Oncol 28(8):1351–1357
Laffleur B, Pascal V, Sirac C, Cogne M (2012) Production of human or humanized antibodies in mice. Methods Mol Biol 901:149–159 (Clifton, NJ)
Larkin J, Chiarion-Sileni V, Gonzalez R, Grob JJ, Cowey CL, Lao CD et al (2015) Combined nivolumab and ipilimumab or monotherapy in untreated melanoma. N Engl J Med 2015(373):23–34
Larkin J, Minor D, D’Angelo S, Neyns B, Smylie M, Miller WH Jr et al (2016) Overall survival in patients with advanced melanoma who received nivolumab versus investigator’s choice chemotherapy in CheckMate 037: a randomized, controlled, open-label phase III trial. J Clin Oncol 0(0):JCO.2016.71.8023
Lassman A, Gan H, Fichtel L, Merrell R, Van Den Bent M, Kumthekar P et al (2015) A phase 1 study evaluating ABT-414 with temozolomide (TMZ) or concurrent radiotherapy (RT) and TMZ in glioblastoma (GBM) (S43. 006). Neurology 84(14 Suppl):S43. 006
Lassman A, van den Bent M, Gan H, Reardon D, Kumthekar P, Butowski N et al (2016) Efficacy of a novel antibody-drug conjugate (ADC), ABT-414, with temozolomide (TMZ) in recurrent glioblastoma (rGBM). Ann Oncol 27(Suppl 6):326PD
Laurent-Puig P, Cayre A, Manceau G, Buc E, Bachet J-B, Lecomte T et al (2009) Analysis of PTEN, BRAF, and EGFR status in determining benefit from cetuximab therapy in wild-type KRAS metastatic colon cancer. J Clin Oncol 27(35):5924–5930
Leach DR, Krummel MF, Allison JP (1996) Enhancement of antitumor immunity by CTLA-4 blockade. Science 271(5256):1734–1736 (New York, NY)
Lemarié CA, Paradis P, Schiffrin EL (2008) New insights on signaling cascades induced by cross-talk between angiotensin II and aldosterone. J Mol Med 86(6):673–678
Li G, Fields C, Parsons K, Guo J, Phillips GL (2010) 223 Trastuzumab-DM1: mechanisms of action and mechanisms of resistance. Eur J Cancer Suppl 8(7):73
Liggett W, Hainsworth J, Spigel D, Meluch A, Raefsky E, Kennedy S et al (2005) Fludarabine/rituximab (FR) followed by alemtuzumab as first-line treatment for patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL): a Minnie Pearl Cancer Research Network phase II trial. J Clin Oncol 23(16 Suppl):6556
Lin P, Owens R, Tricot G, Wilson CS (2004) Flow cytometric immunophenotypic analysis of 306 cases of multiple myeloma. Am J Clin Pathol 121(4):482–488
Liu L, Shao X, Gao W, Bai J, Wang R, Huang P et al (2010a) The role of human epidermal growth factor receptor 2 as a prognostic factor in lung cancer: a meta-analysis of published data. J Thorac Oncol 5(12):1922–1932
Liu JJ, Lin B, Hao YY, Li FF, Liu DW, Qi Y et al (2010b) Lewis(y) antigen stimulates the growth of ovarian cancer cells via regulation of the epidermal growth factor receptor pathway. Oncol Rep 23(3):833–841
Loi S, Michiels S, Lambrechts D, Fumagalli D, Claes B, Kellokumpu-Lehtinen P-L et al (2013) Somatic mutation profiling and associations with prognosis and trastuzumab benefit in early breast cancer. J Nat Cancer Instit djt121
Lonberg N, Huszar D (1995) Human antibodies from transgenic mice. Int Rev Immunol 13(1):65–93
Long G, Mcneil C, Schachter J, Robert C, Ribas A, Arance A et al (2016) Pembrolizumab versus ipilimumab for advanced melanoma: final overall survival analysis of Keynote-006. Asia-Pac J Clin Oncol 12:61–62
Lonial S, Vij R, Harousseau J-L, Facon T, Moreau P, Mazumder A et al (2012) Elotuzumab in combination with lenalidomide and low-dose dexamethasone in relapsed or refractory multiple myeloma. J Clin Oncol 30(16):1953–1959
Lonial S, Dimopoulos M, Palumbo A, White D, Grosicki S, Spicka I et al (2015) Elotuzumab therapy for relapsed or refractory multiple myeloma. N Engl J Med 373(7):621–631
Lonial S, Richardson PG, Mateos M-V, Weisel K, Dimopoulos MA, Moreau P, Sy O, Katz J, Gupta M, Palumbo A (2016) ELOQUENT-2 update: phase III study of elotuzumab plus lenalidomide/dexamethasone (ELd) vs Ld in relapsed/refractory multiple myeloma (RRMM)—identifying responders by subset analysis. J Clin Oncol 34
Lonser RR, Glenn GM, Walther M, Chew EY, Libutti SK, Linehan WM et al (2003) von Hippel-Lindau disease. Lancet 361(9374):2059–2067
Loupakis F, Pollina L, Stasi I, Ruzzo A, Scartozzi M, Santini D et al (2009) PTEN expression and KRAS mutations on primary tumors and metastases in the prediction of benefit from cetuximab plus irinotecan for patients with metastatic colorectal cancer. J Clin Oncol 27(16):2622–2629
Lu Y, Zi X, Zhao Y, Mascarenhas D, Pollak M (2001) Insulin-like growth factor-I receptor signaling and resistance to trastuzumab (Herceptin). J Natl Cancer Inst 93(24):1852–1857
Lundin J, Kimby E, Björkholm M, Broliden P-A, Celsing F, Hjalmar V et al (2002) Phase II trial of subcutaneous anti-CD52 monoclonal antibody alemtuzumab (Campath-1H) as first-line treatment for patients with B-cell chronic lymphocytic leukemia (B-CLL). Blood 100(3):768–773
Luwor RB, Johns TG, Murone C, Huang HS, Cavenee WK, Ritter G et al (2001) Monoclonal antibody 806 inhibits the growth of tumor xenografts expressing either the de2–7 or amplified epidermal growth factor receptor (EGFR) but not wild-type EGFR. Can Res 61(14):5355–5361
Malavasi F, Funaro A, Roggero S, Horenstein A, Calosso L, Mehta K (1994) Human CD38: a glycoprotein in search of a function. Immunol Today 15(3):95–97
Maloney DG, Grillo-López AJ, White CA, Bodkin D, Schilder RJ, Neidhart JA et al (1997) IDEC-C2B8 (Rituximab) anti-CD20 monoclonal antibody therapy in patients with relapsed low-grade non-Hodgkin’s lymphoma. 2188–2195. 1997-09-15 00:00:00
Manders P, Joshua A, Kefford R, Robert C, Ribas A, Hamid O et al (2016) Three-year overall survival for patients with advanced melanoma treated with pembrolizumab in Keynote-001. Asia-Pac J Clin Oncol 12:47–48
Marcus R, Imrie K, Belch A, Cunningham D, Flores E, Catalano J et al (2005) CVP chemotherapy plus rituximab compared with CVP as first-line treatment for advanced follicular lymphoma. Blood 105(4):1417–1423
Maric G, Rose A, Annis MG, Siegel PM (2013) Glycoprotein non-metastatic b (GPNMB): a metastatic mediator and emerging therapeutic target in cancer. OncoTargets Ther 6:839–852
McDermott D, Motzer R, Atkins M, Plimack E, Sznol M, George S (2016) Long-term overall survival (OS) with nivolumab in previously treated patients with advanced renal cell carcinoma (aRCC) from phase I and II studies. J Clin Oncol 34(Suppl):abstr 4507
Merino AG (2011) Monoclonal antibodies. Basic features. Neurologia 26(5):301–306
Mineo J-F, Bordron A, Baroncini M, Maurage C-A, Ramirez C, Siminski R-M et al (2007) Low HER2-expressing glioblastomas are more often secondary to anaplastic transformation of low-grade glioma. J Neurooncol 85(3):281–287
Misale S, Di Nicolantonio F, Sartore-Bianchi A, Siena S, Bardelli A (2014) Resistance to anti-EGFR therapy in colorectal cancer: from heterogeneity to convergent evolution. Cancer Discov 4(11):1269–1280
Mitchell EP, Perez-Soler R, Van Cutsem E, Lacouture ME (2007) Clinical presentation and pathophysiology of EGFRI dermatologic toxicities. Oncology 21(11 Suppl 5):4–9 (Williston Park, NY)
Moja L, Tagliabue L, Balduzzi S, Parmelli E, Pistotti V, Guarneri V et al (2012) Trastuzumab containing regimens for early breast cancer. Cochrane Libr
Morrison SL (1985) Transfectomas provide novel chimeric antibodies. Science 229(4719):1202–1207 (New York, NY)
Morrison C, Zanagnolo V, Ramirez N, Cohn DE, Kelbick N, Copeland L et al (2006) HER-2 is an independent prognostic factor in endometrial cancer: association with outcome in a large cohort of surgically staged patients. J Clin Oncol 24(15):2376–2385
Morschhauser F, Radford J, Van Hoof A, Vitolo U, Soubeyran P, Tilly H et al (2008) Phase III trial of consolidation therapy with yttrium-90–ibritumomab tiuxetan compared with no additional therapy after first remission in advanced follicular lymphoma. J Clin Oncol 26(32):5156–5164
Morschhauser F, Radford J, Van Hoof A, Botto B, Rohatiner AZ, Salles G et al (2013) 90Yttrium-ibritumomab tiuxetan consolidation of first remission in advanced-stage follicular non-Hodgkin lymphoma: updated results after a median follow-up of 7.3 years from the international, randomized, phase III first-line indolent trial. J Clin Oncol 31(16):1977–1983
Moskowitz CH, Nademanee A, Masszi T, Agura E, Holowiecki J, Abidi MH et al (2015) Brentuximab vedotin as consolidation therapy after autologous stem-cell transplantation in patients with Hodgkin’s lymphoma at risk of relapse or progression (AETHERA): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet 385(9980):1853–1862
Moskowitz CH, Zinzani PL, Fanale MA, Armand P, Johnson NA, Radford JA et al (2016) Pembrolizumab in relapsed/refractory classical Hodgkin lymphoma: primary end point analysis of the phase 2 Keynote-087 study. Am Soc Hematol
Motzer RJ, Rini BI, McDermott DF, Redman BG, Kuzel TM, Harrison MR et al (2014) Nivolumab for metastatic renal cell carcinoma: results of a randomized phase II trial. J Clin Oncol 33(13):1430–1437
Motzer RJ, Escudier B, McDermott DF, George S, Hammers HJ, Srinivas S et al (2015) Nivolumab versus everolimus in advanced renal-cell carcinoma. N Engl J Med 373(19):1803–1813
Nagaraja V, Shaw N, Morey A, Cox M, Eslick G (2016) HER2 expression in oesophageal carcinoma and Barrett’s oesophagus associated adenocarcinoma: an Australian study. Eur J Surg Oncol (EJSO) 42(1):140–148
Nagata Y, Lan K-H, Zhou X, Tan M, Esteva FJ, Sahin AA et al (2004) PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients. Cancer Cell 6(2):117–127
Nahta R (2012) Pharmacological strategies to overcome HER2 cross-talk and Trastuzumab resistance. Curr Med Chem 19(7):1065–1075
Nahta R, Esteva FJ (2006) Molecular mechanisms of trastuzumab resistance. Breast Cancer Res 8(6):667–674
Naidoo J, Page D, Li B, Connell L, Schindler K, Lacouture M et al (2015) Toxicities of the anti-PD-1 and anti-PD-L1 immune checkpoint antibodies. Ann Oncol 26(12):2375–2391
Naumnik W, Chyczewska E (2000) The clinical significance of serum soluble interleukin 2 receptor (sIL-2R) concentration in lung cancer. Folia Histochemica Cytobiol 39:185–186 (Polish Academy of Sciences, Polish Histochemical and Cytochemical Society)
Neuberger MS, Williams GT, Mitchell EB, Jouhal SS, Flanagan JG, Rabbitts TH (1985) A hapten-specific chimaeric IgE antibody with human physiological effector function. Nature 314(6008):268–270
Nguyen DD, Cao TM, Dugan K, Starcher SA, Fechter RL, Coutre SE (2002) Cytomegalovirus viremia during Campath-1H therapy for relapsed and refractory chronic lymphocytic leukemia and prolymphocytic leukemia. Clin Lymphoma 3(2):105–110
Nijhof I, Groen R, Lokhorst H, Van Kessel B, Bloem A, Van Velzen J et al (2015) Upregulation of CD38 expression on multiple myeloma cells by all-trans retinoic acid improves the efficacy of daratumumab. Leukemia 29(10):2039–2049
Nijhof IS, Casneuf T, van Velzen J, van Kessel B, Axel AE, Syed K et al (2016) CD38 levels are associated with response and complement inhibitors contribute to resistance in myeloma patients treated with daratumumab. Blood. blood-2016-03-703439
Nimmerjahn F, Ravetch JV (2008) Fcγ receptors as regulators of immune responses. Nat Rev Immunol 8(1):34–47
Norderhaug L, Olafsen T, Michaelsen TE, Sandlie I (1997) Versatile vectors for transient and stable expression of recombinant antibody molecules in mammalian cells. J Immunol Methods 204(1):77–87
O’Brien NA, Browne BC, Chow L, Wang Y, Ginther C, Arboleda J et al (2010) Activated phosphoinositide 3-kinase/AKT signaling confers resistance to trastuzumab but not lapatinib. Mol Cancer Ther 9(6):1489–1502
Olayioye MA, Neve RM, Lane HA, Hynes NE (2000) The ErbB signaling network: receptor heterodimerization in development and cancer. EMBO J 19(13):3159–3167
Olsen E, Duvic M, Frankel A, Kim Y, Martin A, Vonderheid E et al (2001) Pivotal phase III trial of two dose levels of denileukin diftitox for the treatment of cutaneous T-cell lymphoma. J Clin Oncol 19(2):376–388
Oostendorp M, Lammerts van Bueren JJ, Doshi P, Khan I, Ahmadi T, Parren PW et al (2015) When blood transfusion medicine becomes complicated due to interference by monoclonal antibody therapy. Transfusion 55(6pt2):1555–1562
Osterborg A, Dyer M, Bunjes D, Pangalis GA, Bastion Y, Catovsky D et al (1997) Phase II multicenter study of human CD52 antibody in previously treated chronic lymphocytic leukemia. European study group of CAMPATH-1H treatment in chronic lymphocytic leukemia. J Clin Oncol 15(4):1567–1574
Ott P, Pavlick A, Johnson D, Hart L, Infante J, Luke J et al (2016) A phase 2 study of glembatumumab vedotin (GV), an antibody-drug conjugate (ADC) targeting gpNMB, in advanced melanoma. Ann Oncol 27(Suppl 6):1147P
Palumbo A, Chanan-Khan A, Weisel K, Nooka AK, Masszi T, Beksac M et al (2016) Daratumumab, bortezomib, and dexamethasone for multiple myeloma. N Engl J Med 375(8):754–766
Parakh S, Parslow AC, Gan HK, Scott AM (2016a) Antibody-mediated delivery of therapeutics for cancer therapy. Expert Opin Drug Deliv 13(3):401–419
Parakh S, Nguyen R, Opie JM, Andrews MC (2016b) Late presentation of generalised bullous pemphigoid‐like reaction in a patient treated with pembrolizumab for metastatic melanoma. Australas J Dermatol
Paz-Ares L, Mezger J, Ciuleanu TE, Fischer JR, von Pawel J, Provencio M et al (2015) Necitumumab plus pemetrexed and cisplatin as first-line therapy in patients with stage IV non-squamous non-small-cell lung cancer (INSPIRE): an open-label, randomised, controlled phase 3 study. Lancet Oncol 16(3):328–337
Paz-Ares L, Socinski M, Shahidi J, Hozak R, Soldatenkova V, Kurek R et al (2016) Correlation of EGFR-expression with safety and efficacy outcomes in SQUIRE: a randomized, multicenter, open-label, phase III study of gemcitabine-cisplatin plus necitumumab versus gemcitabine-cisplatin alone in the first-line treatment of patients with stage IV squamous non-small cell lung cancer. Ann Oncol mdw214
Peacock N, Saleh M, Bendell J, Rose A, Dong Z, Siegel P et al (2009) A phase I/II study of CR011-vcMMAE, an antibody-drug conjugate, in patients (pts) with locally advanced or metastatic breast cancer (MBC). J Clin Oncol 27(15S):1067
Peeters M, Siena S, Van Cutsem E, Sobrero A, Hendlisz A, Cascinu S et al (2009) Association of progression-free survival, overall survival, and patient-reported outcomes by skin toxicity and KRAS status in patients receiving panitumumab monotherapy. Cancer 115(7):1544–1554
Peeters M, Price TJ, Cervantes A, Sobrero AF, Ducreux M, Hotko Y et al (2010) Randomized phase III study of panitumumab with fluorouracil, leucovorin, and irinotecan (FOLFIRI) compared with FOLFIRI alone as second-line treatment in patients with metastatic colorectal cancer. J Clin Oncol 28(31):4706–4713
Peng W, Chen JQ, Liu C, Malu S, Creasy C, Tetzlaff MT et al (2016) Loss of PTEN promotes resistance to T cell-mediated immunotherapy. Cancer Discov 6(2):202–216
Perez EA, Romond EH, Suman VJ, Jeong J-H, Davidson NE, Geyer CE et al (2011) Four-year follow-up of trastuzumab plus adjuvant chemotherapy for operable human epidermal growth factor receptor 2–positive breast cancer: joint analysis of data from NCCTG N9831 and NSABP B-31. J Clin Oncol 29(25):3366–3373
Perez EA, Dueck AC, McCullough AE, Chen B, Geiger XJ, Jenkins RB et al (2013) Impact of PTEN protein expression on benefit from adjuvant trastuzumab in early-stage human epidermal growth factor receptor 2–positive breast cancer in the North Central Cancer Treatment Group N9831 trial. J Clin Oncol 31(17):2115–2122
Perez EA, Romond EH, Suman VJ, Jeong J-H, Sledge G, Geyer CE et al (2014) Trastuzumab plus adjuvant chemotherapy for human epidermal growth factor receptor 2–positive breast cancer: planned joint analysis of overall survival from NSABP B-31 and NCCTG N9831. J Clin Oncol 32(33):3744–3752
Perrone F, Lampis A, Orsenigo M, Di Bartolomeo M, Gevorgyan A, Losa M et al (2009) PI3KCA/PTEN deregulation contributes to impaired responses to cetuximab in metastatic colorectal cancer patients. Ann Oncol 20(1):84–90
Petrylak D, Kantoff P, Rotshteyn Y, Israel R, Olson W, Ramakrishna T et al (2011) Prostate-specific membrane antigen antibody drug conjugate (PSMA ADC): a phase I trial in taxane-refractory prostate cancer. J Clin Oncol 29(7 Suppl):158
Petrylak DP, Vogelzang NJ, Chatta GS, Fleming MT, Smith DC, Appleman LJ et al (2015) A phase 2 study of prostate specific membrane antigen antibody drug conjugate (PSMA ADC) in patients (pts) with progressive metastatic castration-resistant prostate cancer (mCRPC) following abiraterone and/or enzalutamide (abi/enz). Am Soc Clin Oncol
Pfreundschuh M, Kuhnt E, Trümper L, Osterborg A, Trneny M, Shepherd L et al (2010) Randomised intergroup trial of first line treatment for young low-risk patients (<61 years) with diffuse large B-cell non-Hodgkin’s lymphoma (DLBCL) with a CHOP-like Regimen with or without the anti-CD20 antibody rituximab–6-year follow-up of the mint study of the Mabthera International Trial (MInT) group. Blood 116(21):111
Plesner T, Arkenau H-T, Lokhorst HM, Gimsing P, Krejcik J, Lemech C et al (2014) Safety and efficacy of daratumumab with lenalidomide and dexamethasone in relapsed or relapsed, refractory multiple myeloma. Blood 124(21):84
Pogue-Geile KL, Song N, Jeong J-H, Gavin PG, Kim S-R, Blackmon NL et al (2015) Intrinsic subtypes, PIK3CA mutation, and the degree of benefit from adjuvant trastuzumab in the NSABP B-31 trial. J Clin Oncol 33(12):1340–1347
Pollack VA, Alvarez E, Tse KF, Torgov MY, Xie S, Shenoy SG et al (2007) Treatment parameters modulating regression of human melanoma xenografts by an antibody–drug conjugate (CR390-vcMMAE) targeting GPNMB. Cancer Chemother Pharmacol 60(3):423–435
Postow MA (ed) (2015) Managing immune checkpoint-blocking antibody side effects. Am Soc Clin Oncol
Postow MA, Chesney J, Pavlick AC, Robert C, Grossmann K, McDermott D et al (2015) Nivolumab and ipilimumab versus ipilimumab in untreated melanoma. N Engl J Med 2015(372):2006–2017
Provencio M, Cruz Mora MÁ, Gómez-Codina J, Quero Blanco C, Llanos M, García-Arroyo FR et al (2014) Consolidation treatment with Yttrium-90 ibritumomab tiuxetan after new induction regimen in patients with intermediate-and high-risk follicular lymphoma according to the follicular lymphoma international prognostic index: a multicenter, prospective phase II trial of the Spanish Lymphoma Oncology Group. Leuk Lymphoma 55(1):51–55
Pujade-Lauraine E, Hilpert F, Weber B, Reuss A, Poveda A, Kristensen G et al (2014) Bevacizumab combined with chemotherapy for platinum-resistant recurrent ovarian cancer: the AURELIA open-label randomized phase III trial. J Clin Oncol 32(13):1302–1308
Queen C, Schneider WP, Selick HE, Payne PW, Landolfi NF, Duncan JF et al (1989) A humanized antibody that binds to the interleukin 2 receptor. Proc Natl Acad Sci 86(24):10029–10033
Rai K, Freter C, Mercier R, Cooper M, Mitchell B, Stadtmauer E et al (2002) Alemtuzumab in previously treated chronic lymphocytic leukemia patients who also had received fludarabine. J Clin Oncol 20(18):3891–3897
Ranpura V, Pulipati B, Chu D, Zhu X, Wu S (2010) Increased risk of high-grade hypertension with bevacizumab in cancer patients: a meta-analysis. Am J Hypertens 23(5):460–468
Re GG, Waters C, Poisson L, Willingham MC, Sugamura K, Frankel AE (1996) Interleukin 2 (IL-2) receptor expression and sensitivity to diphtheria fusion toxin DAB389IL-2 in cultured hematopoietic cells. Can Res 56(11):2590–2595
Reck M, Rodríguez-Abreu D, Robinson AG, Hui R, Csőszi T, Fülöp A et al (2016) Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancer. N Engl J Med 375(19):1823–1833
Reichelt U, Duesedau P, Tsourlakis MC, Quaas A, Link BC, Schurr PG et al (2007) Frequent homogeneous HER-2 amplification in primary and metastatic adenocarcinoma of the esophagus. Mod Pathol 20(1):120–129
Rettig WJ, Old LJ (1989) Immunogenetics of human cell surface differentiation. Annu Rev Immunol 7(1):481–511
Ribas A, Puzanov I, Dummer R, Schadendorf D, Hamid O, Robert C et al (2015) Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial. Lancet Oncol 16(8):908–918
Ribas A, Hamid O, Daud A, Hodi FS, Wolchok JD, Kefford R et al (2016) Association of pembrolizumab with tumor response and survival among patients with advanced melanoma. JAMA 315(15):1600–1609
Richards JO, Karki S, Lazar GA, Chen H, Dang W, Desjarlais JR (2008) Optimization of antibody binding to FcγRIIa enhances macrophage phagocytosis of tumor cells. Mol Cancer Ther 7(8):2517–2527
Richardson PG, Jagannath S, Moreau P, Jakubowiak AJ, Raab MS, Facon T et al (2015) Elotuzumab in combination with lenalidomide and dexamethasone in patients with relapsed multiple myeloma: final phase 2 results from the randomised, open-label, phase 1b–2 dose-escalation study. Lancet Haematol 2(12):e516–e527
Ricklin D, Hajishengallis G, Yang K, Lambris JD (2010) Complement: a key system for immune surveillance and homeostasis. Nat Immunol 11(9):785–797
Riechmann L, Foote J, Winter G (1988) Expression of an antibody Fv fragment in myeloma cells. J Mol Biol 203(3):825–828
Rini BI, Halabi S, Rosenberg JE, Stadler WM, Vaena DA, Ou S-S et al (2008) Bevacizumab plus interferon alfa compared with interferon alfa monotherapy in patients with metastatic renal cell carcinoma: CALGB 90206. J Clin Oncol 26(33):5422–5428
Rini BI, Halabi S, Rosenberg JE, Stadler WM, Vaena DA, Archer L et al (2010) Phase III trial of bevacizumab plus interferon alfa versus interferon alfa monotherapy in patients with metastatic renal cell carcinoma: final results of CALGB 90206. J Clin Oncol 28(13):2137–2143
Ritchie M, Tchistiakova L, Scott N (eds) (2013) Implications of receptor-mediated endocytosis and intracellular trafficking dynamics in the development of antibody drug conjugates. MAbs. Taylor & Francis
Ritter CA, Perez-Torres M, Rinehart C, Guix M, Dugger T, Engelman JA et al (2007) Human breast cancer cells selected for resistance to trastuzumab in vivo overexpress epidermal growth factor receptor and ErbB ligands and remain dependent on the ErbB receptor network. Clin Cancer Res 13(16):4909–4919
Rittmeyer A, Barlesi F, Waterkamp D, Park K, Ciardiello F, Von Pawel J et al (2017) Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial. Lancet 389(10066):255–265
Rizvi NA, Brahmer JR, Ou S-HI, Segal NH, Khleif S, Hwu W-J et al (2015) Safety and clinical activity of MEDI4736, an anti-programmed cell death-ligand 1 (PD-L1) antibody, in patients with non-small cell lung cancer (NSCLC). Am Soc Clin Oncol
Rizzieri D (2016) Zevalin®(ibritumomab tiuxetan): after more than a decade of treatment experience, what have we learned? Crit Rev Oncol/Hematol 105:5–17
Robak T, Dmoszynska A, Solal-Céligny P, Warzocha K, Loscertales J, Catalano J et al (2010) Rituximab plus fludarabine and cyclophosphamide prolongs progression-free survival compared with fludarabine and cyclophosphamide alone in previously treated chronic lymphocytic leukemia. J Clin Oncol 28(10):1756–1765
Robak T, Warzocha K, Govind Babu K, Kulyaba Y, Kuliczkowski K, Abdulkadyrov K et al (2017) Ofatumumab plus fludarabine and cyclophosphamide in relapsed chronic lymphocytic leukemia: results from the COMPLEMENT 2 trial. Leuk Lymphoma 58(5):1084–1093
Robert C, Long GV, Brady B, Dutriaux C, Maio M, Mortier L et al (2015a) Nivolumab in previously untreated melanoma without BRAF mutation. N Engl J Med 372(4):320–330
Robert C, Schachter J, Long GV, Arance A, Grob JJ, Mortier L et al (2015b) Pembrolizumab versus ipilimumab in advanced melanoma. N Engl J Med 372(26):2521–2532
Rose AA, Grosset A-A, Dong Z, Russo C, MacDonald PA, Bertos NR et al (2010) Glycoprotein nonmetastatic B is an independent prognostic indicator of recurrence and a novel therapeutic target in breast cancer. Clin Cancer Res 16(7):2147–2156
Rosenberg JE, Hoffman-Censits J, Powles T, Van Der Heijden MS, Balar AV, Necchi A et al (2016) Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial. Lancet 387(10031):1909–1920
Rossi D, Khiabanian H, Spina V, Ciardullo C, Bruscaggin A, Famà R et al (2014) Clinical impact of small TP53 mutated subclones in chronic lymphocytic leukemia. Blood 123(14):2139–2147
Ruf P, Gires O, Jäger M, Fellinger K, Atz J, Lindhofer H (2007) Characterisation of the new EpCAM-specific antibody HO-3: implications for trifunctional antibody immunotherapy of cancer. Br J Cancer 97(3):315–321
Salles G, Seymour JF, Offner F, López-Guillermo A, Belada D, Xerri L et al (2011) Rituximab maintenance for 2 years in patients with high tumour burden follicular lymphoma responding to rituximab plus chemotherapy (PRIMA): a phase 3, randomised controlled trial. Lancet 377(9759):42–51
Sanchez L, Wang Y, Siegel DS, Wang ML (2016) Daratumumab: a first-in-class CD38 monoclonal antibody for the treatment of multiple myeloma. J Hematol Oncol 9(1):51
Sandler A, Gray R, Perry MC, Brahmer J, Schiller JH, Dowlati A et al (2006) Paclitaxel–carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med 355(24):2542–2550
Santin AD, Bellone S, Van Stedum S, Bushen W, Palmieri M, Siegel ER et al (2005) Amplification of c-erbB2 oncogene. Cancer 104(7):1391–1397
Santin AD, Bellone S, Roman JJ, McKenney JK, Pecorelli S (2008) Trastuzumab treatment in patients with advanced or recurrent endometrial carcinoma overexpressing HER2/neu. Int J Gynecol Obstet 102(2):128–131
Scappaticci FA, Skillings JR, Holden SN, Gerber H-P, Miller K, Kabbinavar F et al (2007) Arterial thromboembolic events in patients with metastatic carcinoma treated with chemotherapy and bevacizumab. J Natl Cancer Inst 99(16):1232–1239
Schneeweiss A, Chia S, Hickish T, Harvey V, Eniu A, Hegg R et al (2013) Pertuzumab plus trastuzumab in combination with standard neoadjuvant anthracycline-containing and anthracycline-free chemotherapy regimens in patients with HER2-positive early breast cancer: a randomized phase II cardiac safety study (TRYPHAENA). Ann Oncol 24(9):2278–2284
Scott LJ (2017) Brentuximab vedotin: a review in CD30-positive Hodgkin lymphoma. Drugs 77(4):435–445
Scott AM, Wolchok JD, Old LJ (2012) Antibody therapy of cancer. Nat Rev Cancer 12(4):278–287
Segaert S, Van Cutsem E (2005) Clinical signs, pathophysiology and management of skin toxicity during therapy with epidermal growth factor receptor inhibitors. Ann Oncol 16(9):1425–1433
Segal NH, Verghis J, Govindan S, Maliakal P, Sharkey RM, Wegener WA et al (2013) Abstract LB-159: a phase I study of IMMU-130 (labetuzumab-SN38) anti-CEACAM5 antibody-drug conjugate (ADC) in patients with metastatic colorectal cancer (mCRC). AACR
Sehn LH, Chua N, Mayer J, Dueck G, Trněný M, Bouabdallah K et al (2016) Obinutuzumab plus bendamustine versus bendamustine monotherapy in patients with rituximab-refractory indolent non-Hodgkin lymphoma (GADOLIN): a randomised, controlled, open-label, multicentre, phase 3 trial. Lancet Oncol 17(8):1081–1093
Seiwert TY, Burtness B, Mehra R, Weiss J, Berger R, Eder JP et al (2016) Safety and clinical activity of pembrolizumab for treatment of recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-012): an open-label, multicentre, phase 1b trial. Lancet Oncol 17(7):956–965
Semrad TJ, O’Donnell R, Wun T, Chew H, Harvey D, Zhou H et al (2007) Epidemiology of venous thromboembolism in 9489 patients with malignant glioma. J Neurosurg 106(4):601–608
Shaked Y, Bertolini F, Man S, Rogers MS, Cervi D, Foutz T et al (2005) Genetic heterogeneity of the vasculogenic phenotype parallels angiogenesis: implications for cellular surrogate marker analysis of antiangiogenesis. Cancer Cell 7(1):101–111
Sharma P, Callahan MK, Bono P, Kim J, Spiliopoulou P, Calvo E et al (2016) Nivolumab monotherapy in recurrent metastatic urothelial carcinoma (CheckMate 032): a multicentre, open-label, two-stage, multi-arm, phase 1/2 trial. Lancet Oncol 17(11):1590–1598
Sharma P, Retz M, Siefker-Radtke A, Baron A, Necchi A, Bedke J et al (2017) Nivolumab in metastatic urothelial carcinoma after platinum therapy (CheckMate 275): a multicentre, single-arm, phase 2 trial. Lancet Oncol 18(3):312–322
Shattuck DL, Miller JK, Carraway KL, Sweeney C (2008) Met receptor contributes to trastuzumab resistance of Her2-overexpressing breast cancer cells. Can Res 68(5):1471–1477
Siena S, Sartore-Bianchi A, Lonardi S, Trusolino L, Martino C, Bencardino K et al (2015) Trastuzumab and lapatinib in HER2-amplified metastatic colorectal cancer patients (mCRC): the HERACLES trial. Am Soc Clin Oncol
Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, McGuire WL (1987) Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 235(4785):177–182
Slamon DJ, Leyland-Jones B, Shak S, Fuchs H, Paton V, Bajamonde A et al (2001) Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 344(11):783–792
Slamon D, Eiermann W, Robert N, Pienkowski T, Martin M, Rolski J et al (2009) Phase III randomized trial comparing doxorubicin and cyclophosphamide followed by docetaxel (AC → T) with doxorubicin and cyclophosphamide followed by docetaxel and trastuzumab (AC → TH) with docetaxel, carboplatin and trastuzumab (TCH) in HER2 positive early breast cancer patients: BCIRG 006 study. Cancer Res 69(24 Suppl):62
Smith GP (1985) Filamentous fusion phage: novel expression vectors that display cloned antigens on the virion surface. Science 228(4705):1315–1317 (New York, NY)
Socinski M, Creelan B, Horn L, Reck M, Paz-Ares L, Steins M et al (2016) NSCLC, metastaticCheckMate 026: a phase 3 trial of nivolumab vs investigator’s choice (IC) of platinum-based doublet chemotherapy (PT-DC) as first-line therapy for stage iv/recurrent programmed death ligand 1 (PD-L1)-positive NSCLC. Ann Oncol 27(Suppl 6):LBA7_PR
Soria J-C, Mauguen A, Reck M, Sandler A, Saijo N, Johnson D et al (2012) Systematic review and meta-analysis of randomised, phase II/III trials adding bevacizumab to platinum-based chemotherapy as first-line treatment in patients with advanced non-small-cell lung cancer. Ann Oncol mds590
Sorich M, Wiese M, Rowland A, Kichenadasse G, McKinnon R, Karapetis C (2015) Extended RAS mutations and anti-EGFR monoclonal antibody survival benefit in metastatic colorectal cancer: a meta-analysis of randomized, controlled trials. Ann Oncol 26(1):13–21
Spector NL, Blackwell KL (2009) Understanding the mechanisms behind trastuzumab therapy for human epidermal growth factor receptor 2–positive breast cancer. J Clin Oncol 27(34):5838–5847
Spratlin JL, Cohen RB, Eadens M, Gore L, Camidge DR, Diab S et al (2010) Phase I pharmacologic and biologic study of ramucirumab (IMC-1121B), a fully human immunoglobulin G1 monoclonal antibody targeting the vascular endothelial growth factor receptor-2. J Clin Oncol 28(5):780–787
Starodub A, Ocean AJ, Messersmith WA, Picozzi VJ, Guarino MJ, Bardia A et al (2015) Therapy of gastrointestinal malignancies with an anti-Trop-2-SN-38 antibody drug conjugate (ADC) (sacituzumab govitecan): phase I/II clinical experience. Am Soc Clin Oncol
Stish B, Oh S, Chen H, Dudek A, Kratzke R, Vallera D (2009) Design and modification of EGF4KDEL 7Mut, a novel bispecific ligand-directed toxin, with decreased immunogenicity and potent anti-mesothelioma activity. Br J Cancer 101(7):1114–1123
Sugimoto H, Hamano Y, Charytan D, Cosgrove D, Kieran M, Sudhakar A et al (2003) Neutralization of circulating vascular endothelial growth factor (VEGF) by anti-VEGF antibodies and soluble VEGF receptor 1 (sFlt-1) induces proteinuria. J Biol Chem 278(15):12605–12608
Swain SM, Ewer MS, Cortés J, Amadori D, Miles D, Knott A et al (2013) Cardiac tolerability of pertuzumab plus trastuzumab plus docetaxel in patients with HER2-positive metastatic breast cancer in CLEOPATRA: a randomized, double-blind, placebo-controlled phase III study. Oncologist 18(3):257–264
Swain SM, Baselga J, Kim S-B, Ro J, Semiglazov V, Campone M et al (2015) Pertuzumab, trastuzumab, and docetaxel in HER2-positive metastatic breast cancer. N Engl J Med 372(8):724–734
Taal W, Oosterkamp HM, Walenkamp AM, Dubbink HJ, Beerepoot LV, Hanse MC et al (2014) Single-agent bevacizumab or lomustine versus a combination of bevacizumab plus lomustine in patients with recurrent glioblastoma (BELOB trial): a randomised controlled phase 2 trial. Lancet Oncol 15(9):943–953
Tabernero J, Yoshino T, Cohn AL, Obermannova R, Bodoky G, Garcia-Carbonero R et al (2015) Ramucirumab versus placebo in combination with second-line FOLFIRI in patients with metastatic colorectal carcinoma that progressed during or after first-line therapy with bevacizumab, oxaliplatin, and a fluoropyrimidine (RAISE): a randomised, double-blind, multicentre, phase 3 study. Lancet Oncol 16(5):499–508
Tagawa ST, Ocean AJ, Lam ET, Saylor PJ, Bardia A, Hajdenberg J et al (2017) Therapy for chemopretreated metastatic urothelial cancer (mUC) with the antibody-drug conjugate (ADC) sacituzumab govitecan (IMMU-132). Am Soc Clin Oncol
Tai Y-T, Dillon M, Song W, Leiba M, Li X-F, Burger P et al (2008) Anti-CS1 humanized monoclonal antibody HuLuc63 inhibits myeloma cell adhesion and induces antibody-dependent cellular cytotoxicity in the bone marrow milieu. Blood 112(4):1329–1337
Takei K, Yamazaki T, Sawada U, Ishizuka H, Aizawa S (2006) Analysis of changes in CD20, CD55, and CD59 expression on established rituximab-resistant B-lymphoma cell lines. Leuk Res 30(5):625–631
Tanner M, Hollmen M, Junttila T, Kapanen A, Tommola S, Soini Y et al (2005) Amplification of HER-2 in gastric carcinoma: association with Topoisomerase IIα gene amplification, intestinal type, poor prognosis and sensitivity to trastuzumab. Ann Oncol 16(2):273–278
Teicher BA, Chari RV (2011) Antibody conjugate therapeutics: challenges and potential. Clin Cancer Res 17(20):6389–6397
Teicher BA, Ellis LM (2008) Antiangiogenic agents in cancer therapy. Springer Science & Business Media
Telang S, Rasku MA, Clem AL, Carter K, Klarer AC, Badger WR et al (2011) Phase II trial of the regulatory T cell-depleting agent, denileukin diftitox, in patients with unresectable stage IV melanoma. BMC Cancer 11(1):515
Thatcher N, Hirsch FR, Luft AV, Szczesna A, Ciuleanu TE, Dediu M et al (2015) Necitumumab plus gemcitabine and cisplatin versus gemcitabine and cisplatin alone as first-line therapy in patients with stage IV squamous non-small-cell lung cancer (SQUIRE): an open-label, randomised, controlled phase 3 trial. Lancet Oncol 16(7):763–774
Thompson PA, Tam CS, O’Brien SM, Wierda WG, Stingo F, Plunkett W et al (2016) Fludarabine, cyclophosphamide, and rituximab treatment achieves long-term disease-free survival in IGHV-mutated chronic lymphocytic leukemia. Blood 127(3):303–309
Timmerman JM, Engert A, Younes A, Santoro A, Armand P, Fanale MA et al (2016) Checkmate 205 update with minimum 12-month follow up: a phase 2 study of nivolumab in patients with relapsed/refractory classical Hodgkin lymphoma. Am Soc Hematol
Tol J, Nagtegaal ID, Punt CJ (2009) BRAF mutation in metastatic colorectal cancer. N Engl J Med 361(1):98–99
Tonelli AR, Lottenberg R, Allan RW, Sriram P (2009) Rituximab-induced hypersensitivity pneumonitis. Respiration 78(2):225–229
Tonini G, Vincenzi B, Santini D, Olzi D, Lambiase A, Bonini S (2005) Ocular toxicity related to cetuximab monotherapy in an advanced colorectal cancer patient. J Natl Cancer Inst 97(8):606–607
Topalian SL, Sznol M, McDermott DF, Kluger HM, Carvajal RD, Sharfman WH et al (2014) Survival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumab. J Clin Oncol 32(10):1020–1030
Topp MS, Gökbuget N, Stein AS, Zugmaier G, O’Brien S, Bargou RC et al (2015) Safety and activity of blinatumomab for adult patients with relapsed or refractory B-precursor acute lymphoblastic leukaemia: a multicentre, single-arm, phase 2 study. Lancet Oncol 16(1):57–66
Trastuzumab FDA label (version approved on 01/18/2008). Available from: http://www.fda.gov/cder/foi/label/2008/103792s5175lbl.pdf
Tse KF, Jeffers M, Pollack VA, McCabe DA, Shadish ML, Khramtsov NV et al (2006) CR389, a fully human monoclonal antibody-auristatin E conjugate, for the treatment of melanoma. Clin Cancer Res 12(4):1373–1382
Tuefferd M, Couturier J, Penault-Llorca F, Vincent-Salomon A, Broët P, Guastalla J-P et al (2007) HER2 status in ovarian carcinomas: a multicenter GINECO study of 320 patients. PLoS ONE 2(11):e1138
Untch M, Rezai M, Loibl S, Fasching PA, Huober J, Tesch H et al (2010) Neoadjuvant treatment with trastuzumab in HER2-positive breast cancer: results from the GeparQuattro study. J Clin Oncol 28(12):2024–2031
Usmani S, Sexton R, Ailawadhi S, Shah J, Valent J, Rosenzweig M et al (2015) Phase I safety data of lenalidomide, bortezomib, dexamethasone, and elotuzumab as induction therapy for newly diagnosed symptomatic multiple myeloma: SWOG S1211. Blood Cancer J 5:e334
Vallera DA, Todhunter DA, Kuroki DW, Shu Y, Sicheneder A, Chen H (2005) A bispecific recombinant immunotoxin, DT2219, targeting human CD19 and CD22 receptors in a mouse xenograft model of B-cell leukemia/lymphoma. Clin Cancer Res 11(10):3879–3888
Van Beijnum JR, Nowak-Sliwinska P, Huijbers EJ, Thijssen VL, Griffioen AW (2015) The great escape; the hallmarks of resistance to antiangiogenic therapy. Pharmacol Rev 67(2):441–461
Van Cutsem E, Peeters M, Siena S, Humblet Y, Hendlisz A, Neyns B et al (2007a) Open-label phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy-refractory metastatic colorectal cancer. J Clin Oncol 25(13):1658–1664
Van Cutsem E, Siena S, Humblet Y, Canon J, Maurel J, Bajetta E et al (2007b) An open-label, single-arm study assessing safety and efficacy of panitumumab in patients with metastatic colorectal cancer refractory to standard chemotherapy. Ann Oncol mdm399
Van Cutsem E, Köhne C-H, Hitre E, Zaluski J, Chang Chien C-R, Makhson A et al (2009) Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. N Engl J Med 360(14):1408–1417
Van Cutsem E, Köhne C-H, Láng I, Folprecht G, Nowacki MP, Cascinu S et al (2011) Cetuximab plus irinotecan, fluorouracil, and leucovorin as first-line treatment for metastatic colorectal cancer: updated analysis of overall survival according to tumor KRAS and BRAF mutation status. J Clin Oncol 29(15):2011–2019
van Rhee F, Szmania SM, Dillon M, van Abbema AM, Li X, Stone MK et al (2009) Combinatorial efficacy of anti-CS1 monoclonal antibody elotuzumab (HuLuc63) and bortezomib against multiple myeloma. Mol Cancer Ther 8(9):2616–2624
Verma S, Miles D, Gianni L, Krop IE, Welslau M, Baselga J et al (2012) Trastuzumab emtansine for HER2-positive advanced breast cancer. N Engl J Med 367(19):1783–1791
Vermorken JB, Mesia R, Rivera F, Remenar E, Kawecki A, Rottey S et al (2008) Platinum-based chemotherapy plus cetuximab in head and neck cancer. N Engl J Med 359(11):1116–1127
Vermorken J, Psyrri A, Mesia R, Peyrade F, Beier F, De Blas B et al (2014) Impact of tumor HPV status on outcome in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck receiving chemotherapy with or without cetuximab: retrospective analysis of the phase III EXTREME trial. Ann Oncol mdt574
Vogel CL, Cobleigh MA, Tripathy D, Gutheil JC, Harris LN, Fehrenbacher L et al (2002) Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer. J Clin Oncol 20(3):719–726
Von Minckwitz G, Procter MJ, De Azambuja E, Zardavas D, Knott A, Viale G et al (2017) APHINITY trial (BIG 4-11): a randomized comparison of chemotherapy (C) plus trastuzumab (T) plus placebo (Pla) versus chemotherapy plus trastuzumab (T) plus pertuzumab (P) as adjuvant therapy in patients (pts) with HER2-positive early breast cancer (EBC). Am Soc Clin Oncol
Wang Y, Liu Y, Du Y, Yin W, Lu J (2013) The predictive role of phosphatase and tensin homolog (PTEN) loss, phosphoinositol-3 (PI3) kinase (PIK3CA) mutation, and PI3K pathway activation in sensitivity to trastuzumab in HER2-positive breast cancer: a meta-analysis. Curr Med Res Opin 29(6):633–642
Watanabe T, Masuyama J, Sohma Y, Inazawa H, Horie K, Kojima K et al (2006) CD52 is a novel costimulatory molecule for induction of CD4+ regulatory T cells. Clin Immunol 120(3):247–259
Weber JS, Kähler KC, Hauschild A (2012) Management of immune-related adverse events and kinetics of response with ipilimumab. J Clin Oncol 30(21):2691–2697
Weber JS, D’Angelo SP, Minor D, Hodi FS, Gutzmer R, Neyns B et al (2015a) Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial. Lancet Oncol 16(4):375–384
Weber JS, Yang JC, Atkins MB, Disis ML (2015b) Toxicities of immunotherapy for the practitioner. J Clin Oncol 33(18):2092–2099
Wierda WG, Kipps TJ, Mayer J, Stilgenbauer S, Williams CD, Hellmann A et al (2010) Ofatumumab as single-agent CD20 immunotherapy in fludarabine-refractory chronic lymphocytic leukemia. J Clin Oncol 28(10):1749–1755
Wildiers H, Kim S, Gonzalez-Martin A, LoRusso P, Ferrero J, Smitt M et al (eds) (2013) T-DM1 for HER2-positive metastatic breast cancer (MBC): primary results from TH3RESA, a phase 3 study of T-DM1 vs treatment of physician’s choice. Eur J Cancer (Elsevier Sci Ltd the Boulevard, Langford Lane, Kidlington, Oxford OX5 1GB, Oxon, England)
Wilke H, Muro K, Van Cutsem E, Oh S-C, Bodoky G, Shimada Y et al (2014) Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised phase 3 trial. Lancet Oncol 15(11):1224–1235
Willett CG, Boucher Y, di Tomaso E, Duda DG, Munn LL, Tong RT et al (2004) Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer. Nat Med 10(2):145–147
Winter G, Milstein C (1991) Man-made antibodies. Nature 349(6307):293–299
Winter JN, Weller EA, Horning SJ, Krajewska M, Variakojis D, Habermann TM et al (2006) Prognostic significance of Bcl-6 protein expression in DLBCL treated with CHOP or R-CHOP: a prospective correlative study. Blood 107(11):4207–4213
Wiseman GA, Gordon LI, Multani PS, Witzig TE, Spies S, Bartlett NL et al (2002) Ibritumomab tiuxetan radioimmunotherapy for patients with relapsed or refractory non-Hodgkin lymphoma and mild thrombocytopenia: a phase II multicenter trial. Blood 99(12):4336–4342
Witzig TE (2002) Zevalin™. Drugs Future 27(6):563–568
Witzig TE, White CA, Wiseman GA, Gordon LI, Emmanouilides C, Raubitschek A et al (1999) Phase I/II trial of IDEC-Y2B8 radioimmunotherapy for treatment of relapsed or refractory CD20+ B-cell non-Hodgkin’s lymphoma. J Clin Oncol 17(12):3793–3803
Wolchok JD, Neyns B, Linette G, Negrier S, Lutzky J, Thomas L et al (2010) Ipilimumab monotherapy in patients with pretreated advanced melanoma: a randomised, double-blind, multicentre, phase 2, dose-ranging study. Lancet Oncol 11(2):155–164
Wolchok JD, Kluger H, Callahan MK, Postow MA, Rizvi NA, Lesokhin AM et al (2013) Nivolumab plus ipilimumab in advanced melanoma. N Engl J Med 369(2):122–133
Wolchok J, Chiarion-Sileni V, Gonzalez R, Rutkowski P, Grob J, Cowey C et al (2016) Updated results from a phase III trial of nivolumab (NIVO) combined with ipilimumab (IPI) in treatment-naive patients (pts) with advanced melanoma (MEL) (CheckMate 067). J Clin Oncol 34(Suppl; abstr 9505)
Wu S, Kim C, Baer L, Zhu X (2010) Bevacizumab increases risk for severe proteinuria in cancer patients. J Am Soc Nephrol 21(8):1381–1389
Wuerkenbieke D, Wang J, Li Y, Ma C (2015) miRNA-150 downregulation promotes pertuzumab resistance in ovarian cancer cells via AKT activation. Arch Gynecol Obstet 292(5):1109–1116
Xia MQ, Tone M, Packman L, Hale G, Waldmann H (1991) Characterization of the CAMPATH-1 (CDw52) antigen: biochemical analysis and cDNA cloning reveal an unusually small peptide backbone. Eur J Immunol 21(7):1677–1684
Xu W, Miao KR, Zhu DX, Fang C, Zhu HY, Dong HJ et al (2011) Enhancing the action of rituximab by adding fresh frozen plasma for the treatment of fludarabine refractory chronic lymphocytic leukemia. Int J Cancer 128(9):2192–2201
Yakes FM, Chinratanalab W, Ritter CA, King W, Seelig S, Arteaga CL (2002) Herceptin-induced inhibition of phosphatidylinositol-3 kinase and Akt Is required for antibody-mediated effects on p27, cyclin D1, and antitumor action. Can Res 62(14):4132–4141
Yang X-D, Jia X-C, Corvalan JR, Wang P, Davis CG (2001) Development of ABX-EGF, a fully human anti-EGF receptor monoclonal antibody, for cancer therapy. Crit Rev Oncol/Hematol 38(1):17–23
Yang JC, Haworth L, Sherry RM, Hwu P, Schwartzentruber DJ, Topalian SL et al (2003) A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer. N Engl J Med 349(5):427–434
YERVOY™ (ipilimumab) (2011) US prescribing information: risk evaluation and mitigation strategy (REMS). Bristol-Myers Squibb Company, Princeton, NJ, USA. Available from: http://www.hcp.yervoy.com/
Yonemura Y, Ninomiya I, Yamaguchi A, Fushida S, Kimura H, Ohoyama S et al (1991) Evaluation of immunoreactivity for erbB-2 protein as a marker of poor short term prognosis in gastric cancer. Can Res 51(3):1034–1038
Yonesaka K, Zejnullahu K, Okamoto I, Satoh T, Cappuzzo F, Souglakos J et al (2011) Activation of ERBB2 signaling causes resistance to the EGFR-directed therapeutic antibody cetuximab. Sci Transl Med 3(99):99ra86–99ra86
Younes A, Kadin ME (2003) Emerging applications of the tumor necrosis factor family of ligands and receptors in cancer therapy. J Clin Oncol 21(18):3526–3534
Younes A, Gopal AK, Smith SE, Ansell SM, Rosenblatt JD, Savage KJ et al (2012) Results of a pivotal phase II study of brentuximab vedotin for patients with relapsed or refractory Hodgkin’s lymphoma. J Clin Oncol 30(18):2183–2189
Zaretsky JM, Garcia-Diaz A, Shin DS, Escuin-Ordinas H, Hugo W, Hu-Lieskovan S et al (2016) Mutations associated with acquired resistance to PD-1 blockade in melanoma. N Engl J Med 375(9):819–829
Zeidler R, Reisbach G, Wollenberg B, Lang S, Chaubal S, Schmitt B et al (1999) Simultaneous activation of T cells and accessory cells by a new class of intact bispecific antibody results in efficient tumor cell killing. J Immunol 163(3):1246–1252
Zeidler R, Mysliwietz J, Csanady M, Walz A, Ziegler I, Schmitt B et al (2000) The Fc-region of a new class of intact bispecific antibody mediates activation of accessory cells and NK cells and induces direct phagocytosis of tumour cells. Br J Cancer 83(2):261
Zent CS, Bone ND, Geyer SM, Kay NE (2005) Tumor cells resistant to alemtuzumab complement mediated cytotoxicity in patients with high risk previously untreated early stage CLL: a possible mechanism of treatment failure. Blood 106(11):2973
Zhuang G, Brantley-Sieders DM, Vaught D, Yu J, Xie L, Wells S et al (2010) Elevation of receptor tyrosine kinase EphA2 mediates resistance to trastuzumab therapy. Can Res 70(1):299–308
Zonder JA, Mohrbacher AF, Singhal S, Van Rhee F, Bensinger WI, Ding H et al (2012) A phase 1, multicenter, open-label, dose escalation study of elotuzumab in patients with advanced multiple myeloma. Blood 120(3):552–559
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2020 Springer Nature Switzerland AG
About this chapter
Cite this chapter
Parakh, S., King, D., Gan, H.K., Scott, A.M. (2020). Current Development of Monoclonal Antibodies in Cancer Therapy. In: Theobald, M. (eds) Current Immunotherapeutic Strategies in Cancer. Recent Results in Cancer Research, vol 214. Springer, Cham. https://doi.org/10.1007/978-3-030-23765-3_1
Download citation
DOI: https://doi.org/10.1007/978-3-030-23765-3_1
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-030-23764-6
Online ISBN: 978-3-030-23765-3
eBook Packages: MedicineMedicine (R0)